Membrane Fatty Acid Transporters as Regulators of Lipid Metabolism: Implications for Metabolic Disease

JAN F. C. GLATZ, JOOST J. F. P. LUIKEN, AND AREND BONEN

Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands; and Department of Human Health and Nutritional Sciences, University of Guelph, Guelph, Canada

I. Introduction 368

II. Mechanism of Transmembrane Transport of Fatty Acids 368
   A. Membrane fatty acid transport mediated by lipids or proteins? 369
   B. Evidence for the involvement of membrane proteins 370

III. Membrane-Associated Fatty Acid Transporters 373
   A. Plasma membrane fatty acid binding protein 373
   B. Fatty acid translocase/CD36 374
   C. Fatty acid transport proteins 375
   D. Caveolins 377
   E. Overall conclusions on fatty acid transporters 378

IV. Functioning and Subcellular Localization of Fatty Acid Transporters 378
   A. Subcellular translocation of fatty acid transporters 378
   B. Posttranslational modification of fatty acid transporters 378
   C. Functioning of fatty acid transporters in mitochondrial fatty acid utilization 382
   D. Coordinated functioning of fatty acid transporters 383
   E. Do fatty acid transporters channel fatty acids to a particular metabolic fate? 384

V. Signaling and Trafficking Events Regulating Membrane Transporter Translocation 385
   A. Signaling pathways 385
   B. Trafficking pathways 389

VI. Chronic Physiological Regulation of Fatty Acid Transporters 391
   A. Regulation of fatty acid transporter expression 391
   B. Effects of development, ageing, and gender 392
   C. Effects of fasting, hormones, and exercise training 393

VII. Alterations in Fatty Acid Transporters in Disease 394
   A. Cardiac hypoxic disease and heart failure 394
   B. Insulin resistance and type 2 diabetes 396
   C. Type 1 diabetes 402

VIII. Conclusions and Perspectives 403
   A. Integration of regulatory steps 403
   B. Fatty acid transporters as potential therapeutic targets 404

Glatz JFC, Luiken JJFP, Bonen A. Membrane Fatty Acid Transporters as Regulators of Lipid Metabolism: Implications for Metabolic Disease. Physiol Rev 90: 367–417, 2010; doi:10.1152/physrev.00003.2009.—Long-chain fatty acids and lipids serve a wide variety of functions in mammalian homeostasis, particularly in the formation and dynamic properties of biological membranes and as fuels for energy production in tissues such as heart and skeletal muscle. On the other hand, long-chain fatty acid metabolites may exert toxic effects on cellular functions and cause cell injury. Therefore, fatty acid uptake into the cell and intracellular handling need to be carefully controlled. In the last few years, our knowledge of the regulation of cellular fatty acid uptake has dramatically increased. Notably, fatty acid uptake was found to occur by a mechanism that resembles that of cellular glucose uptake. Thus, following an acute stimulus, particularly insulin or muscle contraction, specific fatty acid transporters translocate from intracellular stores to the plasma membrane to facilitate fatty acid uptake, just as these same stimuli recruit glucose transporters to increase glucose uptake. This regulatory mechanism is important to clear lipids from the circulation postprandially and to rapidly facilitate substrate provision when the metabolic demands of heart and muscle are increased by contractile activity. Studies in both humans and animal models have implicated fatty acid transporters in the pathogenesis of diseases such as the progression of obesity to insulin resistance and type 2 diabetes. As a result, membrane fatty acid transporters are now being regarded as a promising therapeutic target to redirect lipid fluxes in the body in an organ-specific fashion.
I. INTRODUCTION

The importance of long-chain fatty acids and lipids for mammalian homeostasis is well recognized. Fatty acids (for convenience this term is used to designate “long-chain fatty acids,” unless otherwise indicated) are primarily known as constituents of “fat,” which represents a crucial and efficient energy store due to the high energy content per unit weight. Apart from their fundamental role as a fuel for energy production, fatty acids are incorporated into phospholipids forming the core of biological membranes and serve in selected signal transduction pathways to alter gene expression. However, largely due to their hydrophobic properties, fatty acids also exert harmful effects and may cause (acute) cellular injury (96, 235, 468). Taken together, these divergent characteristics of fatty acids require that their transport among and into tissues occurs through specific mechanisms that allow their rapid and controlled distribution without the possible detrimental effects associated with their detergent-like properties.

Dietary fats typically comprise 30–40% of energy intake and consist mostly of long-chain fatty acids esterified in triacylglycerols. Lingual and pancreatic lipases will hydrolyze these triacylglycerols into monoacylglycerol and fatty acids which then are taken up by jejunal and ileal enterocytes, reesterified into triacylglycerols, and incorporated with other lipids, lipid-soluble vitamins, and apolipoproteins into chylomicrons for subsequent secretion into the circulation. Similarly, the liver secretes very-low-density lipoproteins into chylomicrons and apolipoproteins. Both chylomicrons, carrying exogenous lipids, and very-low-density lipoproteins, carrying endogenous lipids, undergo hydrolysis of their triacylglycerols by lipoprotein lipase located at the surface of the capillaries, so as to deliver the fatty acids into peripheral tissues. Fatty acids stored in adipocytes are hydrolyzed by hormone-sensitive lipase (HSL) and adipose tissue triacylglycerol lipase (ATGL), and distributed to other tissues bound to albumin via the circulation. Taken together, a complex system operates to distribute fatty acids among various tissues.

The uptake of fatty acids by parenchymal cells, especially their translocation across the cell membrane, has long been considered to occur by simple (passive) diffusion, with the rate of uptake being determined primarily by the rate of fatty acid delivery (blood flow × extracellular concentration) and the rate of intracellular fatty acid metabolism. However, from a physiological perspective, it would be highly desirable to regulate the entry of fatty acids into the cell to tune their uptake to the metabolic needs and avoid possible harmful effects of excess fatty acid accumulation. Specifically, the objective of such control would be 1) to ensure fatty acid uptake when its extracellular concentration is relatively low, 2) to limit uptake when the extracellular fatty acid concentration is relatively high, 3) potentially select for specific fatty acid types, and 4) allow rapid adjustments in fatty acid provision at the local tissue level to meet rapid fluctuations in metabolic demands, especially in heart and skeletal muscle.

In the past few decades it has become clear that various membrane-associated fatty acid-binding proteins (termed “fatty acid transporters,” for convenience) facilitate the cellular entry of fatty acids, which are then accepted by cytoplasmic fatty acid binding proteins (FABPc). Furthermore, it has been found that acute changes in fatty acid uptake in response to mechanical (e.g., muscle contraction) and hormonal stimuli (insulin) are regulated by specific membrane proteins, in a fashion similar to the regulation of glucose uptake by glucose transporters. Finally, studies in both humans and animal models have implicated the membrane fatty acid transporters in various metabolic aberrations and pathologies. Thus a selective expression and/or regulation of specific (sets of) membrane-associated and cytoplasmic fatty acid-binding proteins could contribute to the control of the fatty acid uptake and utilization processes, thereby enabling tissue-specific fatty acid uptake and utilization independent of fatty acid delivery. However, while FABPc, inside the cell functions as a sink for incoming fatty acids, it displays merely a permissive action in cellular fatty acid uptake in that only its full ablation reduces the rate of cellular fatty acid uptake and utilization (32, 33, 280, 370; for detailed reviews of FABPc, see Refs. 142, 188, 407). In contrast, it appears that specific (sets of) plasma membrane-associated proteins are central to regulating fatty acid uptake and utilization.

In this review we discuss our current understanding of the role of membrane fatty acid transporters in cellular lipid metabolism, focusing on both the acute and chronic regulation of cellular fatty acid uptake and on chronic metabolic diseases, including myocardial disease, insulin resistance, and types 1 and 2 diabetes. Data are presented mostly for heart and skeletal muscle, as these tissues have been studied most intensively, but the concepts to be outlined generally may also apply to other tissues (see sect. VIII). Other related and recent reviews have addressed changes in lipid and carbohydrate metabolism in the failing heart (400), fatty acid metabolism in the type 2 diabetic heart (66), and skeletal muscle lipid metabolism in exercise and insulin resistance (242).
cells, that is, how fatty acid transport occurs across the plasma membrane, between the aqueous phases on either side of this barrier. The dispute centers around the rate-limiting kinetic step in this process, being either the adsorption of fatty acids to, or insertion into, the outer leaflet of the lipid bilayer, the subsequent transfer to the inner leaflet (referred to as flip-flop), or the desorption from the membrane into the aqueous phase (163), and whether one or more membrane proteins could facilitate either one or all of these steps or serve distinct functions in the overall uptake process. Below we discuss specific features and limitations of the methodologies and the experimental models used. The reader is referred to early (161, 163) and more recent (162, 233) reviews of the controversies concerning the rate-limiting processes involved in transferring fatty acids through the plasma membrane.

A. Membrane Fatty Acid Transport Mediated by Lipids or Proteins?

When considering the cellular uptake of fatty acids, the physical transport can be regarded as seven kinetic steps: 1) dissociation of fatty acid from extracellular albumin into the aqueous phase; 2) diffusion through the outer aqueous phase; 3) insertion into the outer leaflet of the phospholipid bilayer; 4) flip-flop from the outer to the inner leaflet, defined as the complete movement of the fatty acid across the bilayer with reorientation of the carboxyl head group from the outer lipid-water interface to the inner lipid-water interface; 5) dissociation from the inner leaflet; 6) diffusion through the inner aqueous phase; and 7) binding to FABPc. Thereafter, the fatty acid may be activated to its acyl-CoA ester and undergo further metabolism.

The aqueous solubility of fatty acids, earlier estimated to be in the micromolar range (395), is now recognized to be extremely low, in the range 1–10 nM (465), indicating that virtually all of the fatty acids will be present in membranes or bound to proteins. The soluble fatty acid binding proteins allow fatty acids to be miscible in aqueous environments. Thus albumin in the circulation and interstitium (348) and FABPc in the cytoplasm (141, 350) act as extracellular and intracellular buffers, respectively, for fatty acids so that under normal physiological conditions (total fatty acid concentration in the range 100–400 μM) generally only <1 part in 10^5 is present in the aqueous phase. In line with this, the average concentration of (non-protein bound) fatty acids in human plasma was reported to be 7.5 ± 2.5 nM (349).

Different approaches and model systems have been used to delineate the rate governing kinetic step in the overall cellular fatty acid uptake process. Various groups have studied fatty acid transport across the lipid bilayer of artificial phospholipid vesicles by incubating these vesicles with fatty acids, or albumin-fatty acid complexes, and monitoring either the appearance of fatty acids in the internal aqueous phase of the vesicle or the change in pH inside the vesicle that occurs as a result of the transmembrane movement of fatty acids. The intravesicular fatty acid concentration has been measured using ADIFAB, a fluorescent probe composed of acrylodan-derivatized intestinal type FABPc that allows the accurate assessment of very low concentrations (nM) of fatty acids in aqueous solutions without disturbing their binding equilibrium with proteins or membranes (351). ADIFAB has been trapped into phospholipid vesicles or erythrocyte ghosts during their formation and has also been microinjected into adipocytes (234). Alternatively, a pH-sensitive fluorophore such as pyranine or 2′,7′-bis(2-carboxyethyl)-5(6)-carboxyfluorescein (BCECF), has been trapped inside phospholipid vesicles, to monitor the H^+ that dissociates from the transported (un-ionized) fatty acid upon its appearance at the inner leaflet of the bilayer (see below) (84; for review, see Ref. 59). In earlier studies transport has also been measured with fluorescently labeled fatty acid analogs (251, 408), but the addition of a large fluorescent moiety is expected to dramatically alter the physicochemical properties of fatty acids, and therefore alter transport rates (233). Because of these considerations, these studies will not be discussed here.

Hamilton and co-workers have monitored the movement of fatty acids across phospholipid membranes using pH-sensitive probes. When presented either as albumin-fatty acid complex, dissolved in organic solvent, or as the K^+ soap, the fatty acids rapidly partition into the outer leaflet of the membrane. Because in such environment the apparent pK_{a} of the fatty acid shifts from ~4.5 in an aqueous solution to ~7.6 (independent of fatty acid type), about half of the fatty acids are present in the un-ionized, i.e., protonated, form. This uncharged species can then easily flip-flop without electrochemical restrictions to the inner leaflet of the membrane, after which a proton is donated to the interior solution and the fatty acid is available for desorption (229). Applying this approach to studies with phospholipid vesicles (230) and with adipocytes (84, 228) revealed linear relationships between the quantity of added fatty acids, the amount of fatty acids that binds to the plasma membrane, and the decrease in intracellular pH. From these various studies it was concluded that binding of the fatty acid to the membrane (adsorption) occurs extremely fast, seems to be diffusion-limited, and is largely independent on the fatty acid chain length, and that transbilayer movement is fast ($t_{1/2} < 1$ s) for all fatty acid types and fast in cells ($<10$ s). These observations have been interpreted to infer that fatty desorption from the membrane may be the rate-limiting step for the overall transport rate of fatty acids, at least for a protein-free model membrane (which represents an
artificial situation). A more recent study has provided further evidence for this concept (383).

Kleinfeld and colleagues (97) used similar model systems to study transmembrane fatty acid transport, applying ADIFAB to detect fatty acid influx, to observe virtually identical overall rates of transport as reported by Hamilton’s group (228). However, in contrast to Hamilton, they concluded that flip-flop is rate-limiting, since their data showed that the dissociation of fatty acids from the membrane is faster than flip-flop (97, 250). The discrepancies with other reports have been attributed to (1) the absence of albumin in some of these other studies which exposes the membranes to high (>5 μM) concentrations of fatty acids that perturb the bilayer structure, and (2) to misinterpretation of the measurements (233). More recently, Kampf and Kleinfeld (232) have used quantitative fluorescence ratio microscopy to measure (noninvasively) fatty acid transport into adipocytes by imaging the intracellular (non-protein bound) fatty acid concentrations (232). Their results indicate that transport rate constants are >50-fold slower in adipocytes than in artificial phospholipid vesicles that contain no proteins, such as are normally present in biological membranes. From these data they conclude that fatty acid transport across adipocyte membranes is highly regulated and best described by a membrane carrier model (for review, see Ref. 233).

In summary, studies in protein-free artificial membranes show that passive flip-flop of the un-ionized form of fatty acids can occur rapidly and in a protein-independent manner across the lipid bilayer phase, indicating that the lipid bilayer does not represent a barrier for fatty acids (Fig. 1A). However, contrary to most findings with these protein-deficient, synthetic lipid vesicles, newer studies with cellular preparations that contain proteins and which apply noninvasive techniques to monitor fatty acid uptake, suggest that flip-flop is the rate-limiting step for fatty acid transport across lipid bilayers (233, 234). Because flip-flop is relatively slow and dependent on the membrane structure (being slower through the ordered phase than through the liquid-crystalline phase), diffusion rates through the lipid bilayer may not be sufficiently rapid to meet the metabolic demands of certain cells and/or under certain conditions, particularly cells in which the metabolic demands for fatty acids can be rapidly upregulated (e.g., heart and skeletal muscle). This implies that at least certain biological tissues may require membrane proteins to catalyze the flip-flop step (231). Such proteins could act as transmembrane transporters for fatty acids, but they could also attract albumin or other fatty acid carriers and enhance the concentration of fatty acids near the membrane surface, which would help overcome the barriers of the unstirred water layer. Another possibility is that membrane proteins act as a sink for fatty acids, as has been proposed for caveolin-1 which has multiple basic residues at its intracellular domain that could interact with the carboxylate anion and in this way accelerate transmembrane fatty acid transport (see sect. nD) (299).

A prevalent view is that both passive diffusion and protein-mediated transport contribute to the cellular uptake of fatty acids. Estimates of the contributions of these two mechanisms have been made by deconvolution of uptake curves and by the use of inhibitors of protein-mediated uptake. Because of saturation of the protein-mediated component at high fatty acid concentration, most of these studies have been interpreted to suggest that protein-mediated uptake is important at physiological concentrations of fatty acids and that passive diffusion becomes predominant at higher, presumably nonphysiological concentrations of fatty acids (2, 3). However, others feel that such data need to be interpreted with caution (161). Still others have questioned the coexistence of diffusional and protein-mediated fatty acid transport across the membrane’s lipid phase and have proposed that fatty acid movement across the plasma membrane is primarily protein mediated (223, 233).

Taken together, the unifying concept arises that during the process of cellular uptake, fatty acids rapidly bind and partition into the plasma membrane, then may undergo lateral diffusion to specific domains such as lipid rafts (333) before their desorption into the intracellular compartment. Membrane proteins thus would function in regulating fatty acid entry into the cell by (1) adsorbing fatty acids from the extracellular media and modulating their transport into the membrane, and (2) segregating or organizing fatty acids for metabolism.

B. Evidence for the Involvement of Membrane Proteins

Starting in the early 1980s, investigators from different laboratories reported that the uptake of fatty acids into various parenchymal cell types showed (1) saturation kinetics, (2) sensitivity to general inhibitors of protein-mediated plasma membrane transport processes (e.g., phloretin and proteases), (3) sensitivity to inhibition by nuclophilic fatty acid derivatives (e.g., sulfo-N-succinimidylololate, SSO; later shown to specifically inhibit CD36, see sect. nAI), and (4) sensitivity to competitive inhibition (5, 6, 287, 412). Although those observations each are in favor of protein-mediated transport, they have been disputed by others (161, 162, 358) who argued that saturation of fatty acid transport can also be explained as saturation of metabolism in combination with passive diffusion. Moreover, the used inhibitors could theoretically inhibit fatty acid uptake via indirect effects on the structural organization of the bilayer, and the fatty acid competition experiments could unveil competition for albumin rather than for transporters.
On the other hand, when (both quiescent and contracting) cardiac myocytes are subjected to increasing concentrations of externally added fatty acids, uptake becomes saturable while the intracellular fatty acid concentration remains low (287, 290). This observation indicates that the metabolic machinery is easily capable of trapping and metabolizing incoming fatty acids during \( V_{\text{max}} \) conditions and that saturation must come from uptake. However, during fatty acid uptake, the major portion of fatty acids is immediately esterified in both quiescent (287) and contracting (290) cardiac myocytes, implying that fatty acid uptake is closely coordinated with subsequent metabolism. For this latter reason, the introduction of giant vesicles for the study of fatty acid transport was a key methodological development (45, 286), as this offered for the first time the means to examine the rates of fatty acid transport in metabolically important mammalian tissues in rodents (44, 45, 253, 272, 286) and in humans (48), independent of concurrent fatty acid metabolism.

**FIG. 1.** A: putative molecular mechanism(s) for the cellular uptake of long-chain fatty acids (FA) and of very-long-chain fatty acids (VLC-FA). 1: In view of their hydrophobic nature, fatty acids could dissociate from their albumin binding sites and cross the plasma membrane by simple diffusion (referred to as uptake by passive diffusion). 2: Alternatively, membrane-associated proteins, such as the peripheral membrane protein FABP\(_{\text{pm}}\) or the transmembrane protein CD36, could act, either alone or together, as acceptor for fatty acids to increase their concentration at the cell surface and thus enhance the number of fatty acid-diffusion events. 3: CD36 itself may also facilitate the transport of fatty acids across the phospholipid bilayer (uptake by facilitated diffusion). Once at the inner side of the cell membrane, fatty acids are bound by cytoplasmic FABP (FABP\(_c\)) before entering metabolic or signaling pathways. 4: Additionally, a minority of fatty acids are thought to be transported by FATP1 and rapidly activated by plasma membrane acyl-CoA synthetase (ACS1) to form acyl-Co esters. 5: VLC-FA are preferentially transported by FATP1 (or other FATPs; see text) and by action of the synthetase activity of FATP1 directly converted into VLC-acyl-CoA esters (uptake by vectorial acylation). B: schematic presentation of the proposed topology of CD36 (two transmembrane domains), with the small cytoplasmic tails palmitoylated. The large extracellular loop has 10 putative N-linked glycosylation sites and two phosphorylation sites. Disulfide bonds between the extracellular cysteines are also shown (between amino acid residues 243–311, 272–333, and 313–323). The NH\(_2\) and COOH termini each contain two palmitoylation sites, and the COOH terminus contains two ubiquitination sites. The shaded area designates a hydrophobic pocket comprised by amino acid residues 93–183 that likely is involved in ligand binding (residues 93–120 was identified as the thrombospondin binding site, residues 120–155 was mapped for oxidized LDL, and residues 139–183 form a multiligand binding site). Arrowheads and numbers indicate the approximate positions of amino acid residues. [Data compiled from Tao et al. (427), Febbraio and Silverstein (125), Ibrahimi et al. (214), and Hoosdally et al. (205).] C: proposed topology of FATP1. Only a short segment of the NH\(_2\) terminus faces the extracellular side of the membrane. Amino acid residues 1–190 are integrally associated with the membrane, while residues 190–257 are cytosolic and contain the AMP-binding motif that mediates the acyl-CoA synthetase activity. Amino acid residues 258–475 are peripherally associated with the inner leaflet of the cell membrane. The COOH terminus is located in the cytoplasm. Arrowheads and numbers indicate the approximate positions of amino acid residues. [Data compiled from Lewis et al. (266) and DiRusso et al. (103).]
Giant vesicles are formed from parenchymal cells by incubation with an appropriate collagenase for that tissue in a high K⁺-containing buffer and are harvested by centrifugation (295, 332). These vesicles have a size (10–15 μm diameter) that is similar to that of small cells, are oriented 100% right-side out, and contain soluble cytoplasmic constituents such as cytoplasmic FABP which will act as a sink for fatty acids that have crossed the plasma membrane (45, 253). Because of the absence of subcellular organelles or metabolic enzymes, giant vesicles can be used to study substrate uptake dissected from metabolism. Studies of the rate of fatty acid entry into rat heart- and skeletal muscle-derived giant vesicles have provided convincing evidence in support of the involvement of a protein-mediated system. In these vesicles, the rate of fatty acid (palmitate) entry is saturable, and inhibitable by 50–70% with protein-modifying agents (trypsin, phlorizin, reactive oleate esters, antisera to putative membrane fatty acid transporters, and with other long-chain (oleate) but not short-chain (octanoate) fatty acids (45, 286, 445). Among heart as well as red and white muscles, the $K_m$ for vesicular fatty acid entry was similar (6–9 nM), while the $V_{max}$ differed markedly and correlated with the fatty acid oxidation capacities of these muscles (Fig. 2). Together, these studies using rat tissue-derived giant vesicles also demonstrated that fatty acids traverse the plasma membrane in heart and skeletal muscle largely via a protein-mediated system, one that is scaled with the capacity to metabolize fatty acids in these tissues.

Although giant plasmaleminal vesicles offer the advantage of conducting substrate uptake studies in metabolically important tissues such as heart, skeletal muscle, adipose tissue, and liver from rodents (41, 44, 45, 253, 273, 286) and human skeletal muscle (48), this model system also has some limitations. For instance, specific subplasmalemal domains may not be included in the vesicle preparation. Specifically, t tubules are completely excluded, while it is known that substrate transport proteins such as GLUT4 are present in t tubules (261, 264). In addition, caution should be taken with the interpretation of experimental data from studies with vesicles from distinct tissues. For instance, in heart and muscle, the driving gradient for net fatty acid movement is always from the extracellular space into the myocyte, while in adipose tissue fatty acid transport may be directed into or out of adipocytes. Therefore, in view of their distinct metabolic functions, muscle tissues (heart and skeletal muscle) and adipose tissue cannot serve as interchangeable model systems for examining the regulation of fatty acid transport (39).

It should be noted that the $K_m$ for vesicular fatty acid entry into heart and skeletal muscle ($K_m = 6–9$ nM; Refs. 44, 45, 286) is similar to the extracellular or circulating concentration of (non-protein bound) fatty acids (~7.5 nM; see sect. II A). Such a close relationship also exists between the transport capacities of the glucose transporter GLUT4 and the lactate transporter MCT1 with their circulating substrate concentrations in vivo, i.e., GLUT4 $K_m = 4.3$ mM (316) and plasma glucose 4–5 mM, MCT1 $K_m = 3.5$ nM and plasma lactate 1–2 mM (55). Thus, for substrate transport, it seems to be a general principle that the $K_m$ of substrate transporters is closely matched to circulating substrate concentrations. This is advantageous, as this allows for highly sensitive protein-mediated transport of circulating substrates, including fatty acids.

In summary, there is a clear role for membrane proteins in the cellular uptake of fatty acids. Although the exact mechanism of transmembrane transport of fatty acids remains largely unknown, i.e., diffusional transbilayer movement of fatty acids in the membrane may occur independently or as part of a protein mediated process, properties of both the lipid bilayer and the fatty acid

![Fig. 2. Characterization of fatty acid transport into giant sarcolemmal vesicles obtained from heart and skeletal muscle. A: kinetics of palmitate transport into giant sarcolemmal vesicles from rat heart and red and white skeletal muscle. B: correlation between the rate of palmitate transport into giant sarcolemmal vesicles and the amount of the fatty acid transporter CD36 located on the plasma membrane of these vesicles. C: correlation between the rate of palmitate transport into giant sarcolemmal vesicles and the fatty acid oxidation capacities of the tissues. [Redrawn from studies by Bonen et al. (45), Glatz et al. (144), and Luiken et al. (286).]]
binding membrane proteins each will influence the uptake process. The presence of an intracellular fatty acid receptor beyond the cell membrane, such as FABPₚₚ, is critical (280). This may explain why in certain cell lines an increased presence of fatty acid transporters in the cell membrane did not increase fatty acid uptake (118, 458, 460). Such concern does not apply to glucose uptake because of its miscibility in the cytoplasm.

III. MEMBRANE-ASSOCIATED FATTY ACID TRANSPORTERS

The early observations of saturation kinetics of fatty acid transport (5, 6, 412) already triggered the search for membrane proteins that act as fatty acid transporters (172–174, 371, 413–416, 437, 438). Since then, different groups have identified integral and peripheral membrane proteins that appeared to be involved in the transport of fatty acids into parenchymal cells. For convenience, these proteins are commonly referred to as “fatty acid transporters,” despite the remaining uncertainty as to the exact mechanism by which any one of these proteins participates in the transport process within the plasma membrane. Table 1 provides a listing of putative fatty acid transporters identified to date, together with their occurrence. Strikingly, these proteins differ in molecular mass and degree of posttranslational modification; some show a characteristic pattern of tissue distribution, while others are ubiquitously expressed. Interestingly, the FATPs form a family of six proteins. Support for facilitating long-chain fatty acid transport by each of these differing transporters (with the exception of caveolin-1) has been obtained from genetic studies in cell lines [plasma membrane-associated FABP (FABPₚₚ) (217), CD36 (214), FATP1-6 (104, 159, 160, 268)], as well as from studies in tissues of genetically altered animals [FABPₚₚ (85, 200, 315), CD36 (42, 86, 123, 153), FATP1 (80, 479), FATP4 (315)].

A. Plasma Membrane Fatty Acid Binding Protein

In mammalian tissues, FABPₚₚ, was originally identified by Stremmel et al. in rat liver (416) and jejunal microvilli (414), and later in adipose tissue (336, 378) and cardiac myocytes (393, 411), all of which are cells with high transmembrane fluxes of fatty acids. FABPₚₚ is peripherally bound at the outer leaflet of the plasma membrane, as FABPₚₚ from rat liver could be isolated by a high-ionic-strength medium (394). Antibodies directed against rat liver FABPₚₚ were found to inhibit fatty acid uptake by hepatocytes (415, 416), jejunal microvilli (414), adipocytes (378), cardiomyocytes (393, 411), and cardiac and skeletal muscle-derived giant vesicles (286, 445) by 50–75%. This suggested that at least a substantial portion of overall fatty acid uptake involved the binding of fatty acids by FABPₚₚ and that the same, or a very similar, protein is expressed in these distinct tissues. In addition, these studies do not rule out the contributions of other

<table>
<thead>
<tr>
<th>Table 1. Membrane-associated putative fatty acid transporters</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Protein (Current Designation)</strong></td>
</tr>
<tr>
<td>----------------------------------</td>
</tr>
<tr>
<td>Plasma membrane fatty acid binding protein (FABPₚₚ)</td>
</tr>
<tr>
<td>FA transport protein (FATP)</td>
</tr>
<tr>
<td>FATP1</td>
</tr>
<tr>
<td>FATP2</td>
</tr>
<tr>
<td>FATP3</td>
</tr>
<tr>
<td>FATP4</td>
</tr>
<tr>
<td>FATP5</td>
</tr>
<tr>
<td>FATP6</td>
</tr>
<tr>
<td>Fatty acid translocase/CD36</td>
</tr>
<tr>
<td>Caveolin-1</td>
</tr>
</tbody>
</table>

The designation “fatty acid transporter” is used for convenience but does not necessarily imply a classic transmembrane transport mechanism such as that of GLUT4. The proteins share the feature of facilitating the transmembrane translocation of (long-chain) fatty acids, although the role of caveolins in fatty acid transport remains controversial (see sect. II.D). Tissue occurrence refers to tissues for which the expression (mRNA or protein) was reported. Relative occurrence is not always clear, as this may differ across species and will depend among other things on developmental and nutritional status, muscle and cardiac activity, and health status. *Glycosylated protein mass. The mass of the nonglycosylated protein is 53 kDa. Glycosylation may differ in some tissues, such as mammary gland, where CD36 molecular mass is ≈ 75 kDa.
fatty acid binding proteins, as inhibition of fatty acid transport by FABP<sub>pm</sub> antibodies was incomplete.

Analysis of its amino acid sequence showed FABP<sub>pm</sub> to be identical to the mitochondrial aspartate aminotransferase (mAspAt) (26, 419). FABP<sub>pm</sub> and mAspAt are derived from the same gene while not requiring alternative splicing of the mRNA (51). Apparently, FABP<sub>pm</sub>/mAspAt is a protein with distinct functions at different subcellular sites. In Xenopus laevis oocytes (484), 3T3 fibroblasts (217), and rat skeletal muscle (85, 200), transfected with mAspAt cDNA, FABP<sub>pm</sub>/mAspAt was localized both to the mitochondria (200) and to the plasma membrane (85, 200, 217, 484). This increased the rates of fatty acid transport into giant sarcolemmal vesicles obtained from skeletal muscle (85, 200). However, the relative increase in plasmalemmal FABP<sub>pm</sub> (+173%) was far in excess of the increase in fatty acid transport (+79%) (85), suggesting that the transport capacity of FABP<sub>pm</sub> alone is perhaps modest.

1. Effects of FABP<sub>pm</sub> on fatty acid metabolism

FABP<sub>pm</sub> overexpression in skeletal muscle did not alter triacylglycerol formation, but fatty acid oxidation was increased (85, 200). This was attributable to additional fatty acids transported into the muscle cell, as the concurrent overexpression of FABP<sub>pm</sub>/mAspAt in mitochondria did not alter fatty oxidation by isolated mitochondria (200; see also sect. nB). There is some evidence for cooperation of FABP<sub>pm</sub> with other fatty acid transporters, specifically CD36 (see sect. nA) (75). Ablation studies of FABP<sub>pm</sub>/mAspAt have not yet been performed.

B. Fatty Acid Translocase/CD36

Studies by Abumrad and co-workers on the inhibitory action of reactive sulfo-N-succinimidy esters of long-chain fatty acids (SSO, see sect. nB) on fatty acid uptake by rat adipocytes (172–174) led to the identification of an integral membrane protein designated (putative) membrane fatty acid translocase (4) that appeared identical to leukocyte cluster-of-differentiation antigen CD36 (glycoprotein IV), now recognized as a class B scavenger receptor protein with multiple functions, particularly the binding of thrombospondin, oxidized low-density lipoprotein (LDL), and anionic phospholipids, and its action as a gustatory lipid sensor (124, 125, 212, 241, 417, 420). CD36 is a 472-amino acid (53 kDa) protein that has a hairpin membrane topology with two transmembrane spanning regions, with both the NH<sub>2</sub> and COOH termini as short segments in the cytoplasm (427) (Fig. 1B). The NH<sub>2</sub>-terminal hydrophobic domain appears to serve as a transmembrane anchor (427). The protein is heavily glycosylated (10 predicted N-linked glycosylation sites situated in the large extracellular loop), has two phosphorylation sites (Thr-92 and Ser-237) and three external disulfide bridges, and contains four palmitoylation sites (225, 427), two each at the extreme NH<sub>2</sub> and COOH termini (cysteines 3, 7, 464, and 466) (see sect. nB1). The COOH-terminal domain also contains two ubiquitination sites (Lys-469 and Lys-472) (see sect. nB3). Studies in rat hepatoma cells suggest that the COOH-terminal YCAR motif is required for CD36 localization to the cell surface and to enhance long-chain fatty acid uptake (119).

The extensive glycosylation increases the apparent mass of CD36 from 53 to 88 kDa (Table 1). However, it was recently shown that mature glycosylation is not necessary for surface expression of CD36 in mammalian cells (205). CD36 is associated with the cholesterol- and sphingolipid-rich membrane microdomains known as rafts (or as caveolae when they contain caveolin). The role of caveolae in CD36 functioning is discussed in section nD. Whether caveolins are involved in targeting CD36 to the plasma membrane is not entirely clear given some contradictory evidence among studies in the heart (14, 15), mouse embryonic fibroblasts (354), and 3T3-L1 fibroblasts and adipocytes (333, 334). Alternatively, palmitoylation of each of the cytoplasmic tails could help recruit CD36 to these membrane microdomains. In this respect, palmitoylation is often involved in regulation of intracellular trafficking and localization of membrane proteins (reviewed in Ref. 149), especially in the trafficking of these proteins to lipid rafts and/or caveolae.

CD36 is ubiquitously expressed in many tissues, as well as endothelial cells, platelets, and macrophages, and is involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism (for review, see Refs. 124, 125). In vitro studies showed that CD36 purified from adipose tissue binds long-chain but not short-chain fatty acids (16, 225). A key role for CD36 in fatty acid transport was demonstrated when Ob17PY fibroblasts (214), C2C12 fibroblasts (20), and skeletal muscle (315) were transfected with CD36, which resulted in increased rates of fatty acid uptake. However, others have found that transfecting CD36 into CHO cells fails to increase fatty acid uptake under basal conditions (118, 460) or when insulin was used to increase plasmalemmal CD36 (460), suggesting that in these cells, such an increase requires additional proteins, or a protein activation step. CD36 is also required both for the uptake of very-long-chain fatty acids (VLCFAs) in cultured cells and for the intestinal absorption of dietary VLCFAs in mice (110). CD36 can also function as a cell adhesion molecule or as a class B scavenger receptor (124, 125). Finally, CD36 appears to be a selective and nonredundant sensor of microbial diacylglycerides (192). This CD36 versatility for a wide variety of ligands may possibly be due to differences in the glycosylation of the protein and/or specific interaction with other proteins or membrane constituents.
1. Effects of CD36 on basal fatty acid metabolism

Under basal conditions, a null mutation in murine CD36 reduced the uptake of the fatty acid analogs 15-(p-iodophenyl)-3-(R,S)-methyl pentadecanoic acid (BMIPP) and 15-(p-iodophenyl)pentadecanoic acid (IPP) in vivo in heart (−50 to −80%), skeletal muscle (−40 to −75%), and adipose tissue (−60 to −70%) (86). CD36 null mice did not show alterations in fatty acid uptake by the liver (86), an organ with absent or very low CD36 expression (123, 253, 272). Comparable reductions were also observed in studies using a naturally occurring fatty acid (palmitate) in CD36 null skeletal muscles (−23%) (42), but not in CD36 null cardiac myocytes (153), presumably due to the compensatory twofold overexpression of FATP1 in CD36 null cardiac myocytes (153).

In perfused, CD36-null murine muscles, the basal rates of fatty acid oxidation (−28%) and triacylglycerol formation (−38%) were reduced (42). Similarly, in CD36 null cardiac myocytes, there was a 25% reduction in fatty acid oxidation (216), which was restored by transgenic rescue of CD36 (216). There were also reductions in intracellular triacylglycerol concentrations in perfused CD36 null hearts (−27 to −64%; Refs. 86, 216) and in skeletal muscle (−70%; Ref. 86). This was likely due to a reduction in the basal rate of triacylglycerol esterification in CD36 null mice (−38%, in red muscles; Ref. 42). In contrast to these studies in CD36 null mice, no changes in basal rates of fatty acid metabolism were observed in isolated soleus muscles of CD36-overexpressing mice (213), presumably since rates of fatty acid metabolism are low in isolated muscle that are at complete rest (see below).

2. Effects of CD36 on fatty acid metabolism during metabolic challenges

Examining the role of CD36 on fatty acid metabolism under basal conditions has underestimated its role in regulating fatty acid uptake and metabolism. Metabolic challenge studies have now been performed in isolated muscles of CD36 overexpressing mice (213) and in hindlimb muscles (42), hearts (258), and cardiac myocytes (153) of CD36 null mice, using stimuli that are known to contribute to altered rates of fatty acid metabolism. For example, in working hearts, fatty acid oxidation remained 40–60% lower in CD36 null than in WT mice (254, 258), and in CD36 null muscle, AICAR-stimulated fatty acid oxidation was also markedly impaired (KO +38%; WT +100%; Ref. 42). Conversely, in CD36 overexpressing mice, muscle contraction increased fatty acid oxidation by +400%, while in WT mice, the increase was much less, i.e., +100%. Insulin-stimulated triacylglycerol esterification in CD36 null red muscle (+34%) was increased much less than in red muscles of WT mice (+70%) (42). Since the cellular signaling pathways and enzymatic activities are not altered in CD36 null mice (42, 86, 153), these studies demonstrate that CD36 contributes markedly to the regulation of fatty acid oxidation and esterification in heart and skeletal muscle, particularly during metabolic challenges.

C. Fatty Acid Transport Proteins

Schaffer and Lodish (371) used an expression cloning strategy to identify a protein that, when expressed in COS7 cells, increased the uptake of fluorescently labeled fatty acids. This 646-amino acid fatty acid transport protein (FATP; recently renamed as FATP1) is an integral membrane protein that has six membrane-spanning regions. Subsequently, others disclosed the existence of a family of integral membrane FATPs, referred to as FATP2-6 (139, 191). These FATP isoforms are expressed in somewhat of a tissue-specific manner (Table 1) (107, 469).

FATP1 contains a hydrophobic NH2-terminal region (residues 1–190) that is integrally associated with membranes, whereas amino acid residues 258–313 and 314–475 are only peripherally membrane associated, and residues 191–257 and 476–646 do not direct membrane association and likely face the cytosol (206) (Fig. 1C). The mechanism of action for FATP1 involves ATP binding that is dependent on serine-250 of the IYTSGTGXP motif (residues 247–257) (347, 418). FATP1 may also form detergent-resistant dimers that have a functional role in fatty acid transport (347). The region between amino acid residues 191–475 is sufficient to allow an association of FATP1s (347). Both the monomeric (−63 kDa) and oligomeric forms (−130 kDa) are present in NIH 3T3 cells (347).

FATP1 is expressed in many tissues, including brain, kidney, lung (191), skin (375), adipose tissue (107), heart (73, 80, 107, 139, 153, 181), and skeletal muscle (42, 46, 107, 219, 315) (Table 1). FATP2 is expressed primarily in liver and kidney (183, 191, 226, 366) as well as in the intestines (190), whereas FATP3 has a more restricted distribution being expressed in liver, lung, testis, and skin.
FATP4 is expressed in intestine, brain, kidney, liver, skin, lung, heart, and skeletal muscle (107, 153, 181, 185–187, 191, 219, 315, 375). In contrast, FATP5 is only expressed in liver (105, 191, 209). Finally, although FATP6 was deemed to be heart specific (139), this protein is expressed in a number of other tissues, including skeletal muscle, placenta, testis, adrenal glands, kidney, bladder, uterus, and skin (139, 181, 219, 375).

1. Fatty acid transport roles of FATPs

Expression of the murine FATPs in a genetically defined yeast strain increased fatty acid transport with varying degrees of effectiveness. FATP1, -2, and -4 are particularly effective in facilitating the rates of long-chain fatty acid transport by 8.2-, 4.5-, and 13.1-fold, respectively, whereas FATP3 and -5 provide only a modest 2-fold increase, and FATP6 provides virtually no increase in long-chain fatty acid transport (104). However, studies in other models suggest somewhat different fatty acid transport roles for FATPs. In MA-10 Leydig cells, FATP3 expression failed to alter fatty acid transport (328). Knockdown studies of FATP1 (3T3-L1 adipocytes) revealed that basal fatty acid uptake was reduced (268), whereas with FATP4 knockdown (3T3-L1 adipocytes) or overexpression (HEK-293 cells), there were no changes in fatty acid uptake (268). Another study has indicated that FATP4 is not present at the plasma membrane and is not a fatty acid transporter in a wide variety of cultured cells (300). In contrast, experiments in rat skeletal muscle indicated that FATP1 and -4 have fatty acid transport function, with FATP4 being more effective than FATP1 (315), as was also observed in yeast (104). Others have shown that the transport capacity of FATPs in 293 cells depends on the fatty acid used (palmitate transport: FATP6 >> FATP1 > FATP4; olate transport: FATP4 > FATP1 = FATP6) (139), suggesting that different FATPs transport specific fatty acids with different efficiencies. Thus the claim that FATP6 is the most important fatty acid transporter in the heart (139) is premature. Interestingly, in vitro FATP5 from liver exhibits both fatty acid transport and bile acid-CoA ligase activity (104, 107, 191, 209).

The differing transport capacities for the same FATP isoform among several studies may indicate that there may well be cell-type specific responses, whereby the functioning of the FATP isoforms may depend on the presence and/or interaction with other proteins or membrane constituents. Therefore, some care is required when using cultured cell lines to extrapolate the function of FATPs and other fatty acid transporters to the in vivo situation in mammalian tissues, as all the necessary biochemical transport and/or trafficking machinery normally present in mammalian tissues may be incomplete in selected cell lines, as has been suggested in several recent studies (118, 460).

To elucidate the in vivo roles of the FATPs, generation of transgenic mice has been undertaken for FATP1, -4, and -5. Cardiac-specific overexpression (8-fold) of FATP1 increased the rate of fatty acid uptake (4-fold) (80). In contrast, ablation of FATP1 did not reduce basal rates of fatty acid uptake, either in adipocytes or in skeletal muscle (479). Combined, these findings may indicate that FATP1 is a functionally important fatty acid transporter but only at nonphysiologically high expression levels, and that at normal expression levels it contributes minimally to the bulk uptake of fatty acids in muscle tissues. Nevertheless, during metabolic challenges, the role of FATP1 might become more important, as it was reported that insulin-stimulated fatty acid uptake is markedly reduced in FATP1 null muscle (479). Deletion of one allele of FATP4 resulted in 48% reduction of FATP4 protein levels and a 40% reduction of BODIPY-fatty acid uptake by isolated enterocytes, but did not affect intestinal fat absorption either with normal diet or with a high-fat diet (138). Deletion of both FATP4 alleles resulted in early embryonic lethality (138, 187), possibly as a result of reduced fat absorption in association with FATP4 deletion from the epithelial cells of the visceral endoderm and the brush-border membrane of extraembryonic endodermal cells, as well as neonatally lethal restrictive dermopathy (187). In epidermal keratinocytes, FATP4 is essential for the maintenance of a normal epidermal structure (186). FATP5 null mice showed a decreased fatty acid uptake rate (~50%) in primary hepatocytes and reduced hepatic fatty acid and triacylglycerol contents (105). Knockdown of hepatic FATP5 in vivo resulted in a marked reduction of hepatic dietary fatty acid uptake, reduced caloric uptake, and concomitant protection from diet-induced nonalcoholic fatty liver disease (106). Defective bile acid conjugation, which relates to the bile acid-CoA synthetase activity of FATP5, has been observed in FATP5 null mice (209).

2. Very-long-chain acyl-CoA synthetase activity of FATPs

In early studies on FATPs, it was found that these proteins shared considerable sequence homologies and domain organization to acyl-CoA synthetases, suggesting that FATPs are members of the superfamily of adenylyl forming acyl-CoA synthetases, particularly very-long-chain acyl-CoA synthetases (VLACS) for >C22 (120, 371, 470, 471). However, in vivo very-long-chain fatty acids constitute only a small fraction of the total fatty acid pool. For example, in dogs fatty acids ≥C22 constitute 0.5% of the circulating fatty acids and 1.8% of the triacylglycerol fatty acids (456). Circulating fatty acids and triacylglycerols are largely comprised (~90%) of long-chain (C16:0-C18:2) fatty acids in dogs (456) and rodents (145), and this is also reflected in the makeup of intramuscular lipids.
3. Long-chain acyl-CoA synthetases

Expression of fatty acyl-CoA synthetases that are unrelated to the FATP-associated VLACS can enhance fatty acid uptake in *Escherichia coli* (292, 373, 472), yeast (432), and 3T3-L1 adipocytes (136, 346), suggesting that vectorial acylation may drive fatty acid transport. In 3T3-L1 adipocytes, ACS1 is an integral membrane protein which colocalizes and interacts with FATP1 (136, 346). Overexpression of each of these two proteins increases fatty acid uptake, and their concomitant overexpression has a synergistic effect on fatty acid uptake (136), while blocking ACS1 activity reduces fatty acid uptake (346). However, these studies (136, 292, 346, 373, 432, 472) should not be taken to imply that the formation of fatty acyl-CoAs (vectorial acylation) obviates the need for a fatty acid transport mechanism. Instead, fatty acid transport and ACS1 activity are most likely complementary processes, comparable to that of GLUT4-facilitated glucose transport and hexokinase II activity in vivo (130–135). Indeed, in skeletal muscle, the coordinated expression of CD36 and ACS1 in red and white muscles, and in chronically stimulated muscles ($r = 0.98$) is an example of functional complementarity between these proteins, as this allows a greater rate of fatty acids to be transported into the muscle cell via CD36, which can then be activated by ACS1 (279).

The independence of fatty acid transport from vectorial acylation has been shown in a number of studies. First, with giant vesicles there is no evidence for any fatty acid metabolism, because incoming fatty acids were retrieved as fatty acids in the vesicular lumen, most likely bound to cytoplasmic FABP (45, 286). Second, studies by DiRusso et al. (104) have resolved some of the confusion concerning the fatty acid transport functions and acyl-CoA synthetase activities of FATPs. Expression of the murine FATP1-6 in a genetically defined yeast strain, which normally cannot transport long-chain fatty acids, and which has a reduced VLACS activity, demonstrated the independent fatty acid transport capacities from the VLACS activity of many of these FATP isoforms. Specifically, FATP1-5 expression, but not FATP6, increased fatty acid transport differentially, i.e., 2.3-fold (FATP3 and -5), 4.4-fold (FATP2), 8-fold (FATP1), and 13-fold (FATP4). Concomitantly, these proteins only marginally altered oleoyl-CoA synthase activity (104) while, except for FATP5, VLACS activity was increased for all other FATPs (range 2- to 24-fold; Ref. 104). Thus FATP isoforms appear to play unique roles in fatty acid trafficking, including the transport of exogenous long-chain fatty acids (FATP1-5) and very-long-chain fatty acid activation (FATP1-4, -6). Importantly, these studies also demonstrated that the fatty acyl activation function of FATPs is not required for long-chain (C:14-C:18) fatty acid transport (104).

In summary, it appears that the fatty acid transport function of FATPs is not attributable to their FATP-associated VLACS activity, which is very low compared with ACS1 activity. Moreover, ACS1 activity by itself also does not account for fatty acid transport. Instead, in vivo, FATPs, and likely other fatty acid transporters, act in a concerted fashion with ACS1 as functional complex, to take up and activate fatty acids, thereby maintaining an effective transplasmalemmal fatty acid gradient and coupling fatty acid transport to its metabolism.

D. Caveolins

Caveolins are the defining protein constituents of caveolae, which are specialized microdomains of the plasma membrane, enriched in cholesterol, sphingomyelins, and signaling and receptor proteins (88, 327). Caveolins are responsible for the invagination of the plasma membrane, giving the caveolar microdomains their flask-shaped appearance. They are small integral membrane proteins (~22 kDa) with an additional hydrophobic scaffolding domain for binding to other proteins. Currently, three members of the caveolin family have been identified. Caveolin-1 and -2 have a relatively ubiquitous distribution pattern in mammalian tissues with the exception of muscle tissues, whereas caveolin-3 is the predominant isoform in muscle and heart (88, 148).

Unexpectedly, a screen for high-affinity fatty acid binding proteins within adipocyte plasma membranes us-
helped in establishing the roles of FABPpm, CD36, FATPs, and caveolins in cellular fatty acid uptake. One remarkable issue is that all fatty acid transporters also appear to have functions that are unrelated to fatty acid transport; for example, FABP<sub>pm</sub> and the FATPs contain mAspAt activity and VLACS activity, respectively; CD36 displays multiple other functions, including thrombospondin binding; caveolins possess the ability to form caveolar regions. This notion should not be taken to preclude a significant role for these proteins in the regulation of fatty acid flux across the plasma membrane. Importantly, there are numerous unresolved issues concerning the fatty acid transporters: 1) their three-dimensional protein structure and membrane topology; 2) their specific mode of action including possible interactions with each other and with other proteins; 3) their possible substrate specificity, i.e., the relative affinity towards saturated versus unsaturated and polyunsaturated fatty acid species; and 4) their ability to couple fatty acid uptake to channeling into distinct metabolic pathways (see sect. IVD). Moreover, the listing of fatty acid transporters may not be complete, as suggestions have been made that other fatty acid proteins may yet be identified (cf. Ref. 234). Finally, as mentioned above (see sect. II B), caution should be taken by using any one cell type or mammalian tissue as a universal model for fatty acid transport or transporters. In view of the distinct metabolic roles of selected tissues and differences in bidirectional (adipose tissue) and monodirectional (heart, muscle, liver) transmembrane fatty acid fluxes, the expression and functioning of the various fatty acid transporters may well be quite dissimilar.

### IV. FUNCTIONING AND SUBCELLULAR LOCALIZATION OF FATTY ACID TRANSPORTERS

The studies reviewed in the previous section have established that a number of distinct membrane proteins facilitate the transport of fatty acids across the plasma membrane. Insight into the functioning and physiological significance of these fatty acid transporters was obtained from studies in which it was shown that fatty acid transporters can traffic between intracellular depots, and the plasma membrane and mitochondria in response to physiological perturbations (muscle contraction, exercise, insulin), and from studies on posttranslational modification of fatty acid transporters, as will be outlined below.

#### A. Subcellular Translocation of Fatty Acid Transporters

The observation that muscle-specific overexpression of CD36 increased fatty acid uptake only during muscle contraction (213) triggered us to investigate the possibil-
ity that in response to muscle contraction CD36 would translocate from a putative intracellular storage site to the sarcolemma to increase fatty acid uptake. Such a mechanism would resemble the well-known regulation of muscle glucose uptake by subcellular translocation of GLUT4 (for review, see Refs. 99, 208, 362, 365, 428).

1. Contraction-mediated regulation of fatty acid transport and transporters

The first evidence that fatty acid uptake was regulated acutely at the level of the plasma membrane was obtained from studies in which the metabolic demands of skeletal muscle in vivo were increased via electrically induced contraction (44). Almost immediately with the onset of muscle contraction there was an increase in the rate of fatty acid transport into giant sarcolemmal vesicles prepared from these muscles (+20–29% after 1–5 min) with a maximal 1.8-fold increase being attained after 30 min. Upon cessation of muscle contraction for 20 min, rates of fatty acid transport returned to basal rates. The contraction-induced increases in fatty acid transport rates were linearly related with the intensity of the muscle contraction, indicating that fatty acid uptake into muscle scaled with the muscles’ metabolic demands. These studies also revealed for the first time that the contraction-induced increase in fatty acid transport was accompanied by a concurrent translocation of a fatty acid transporter, CD36, from an intracellular depot to the plasma membrane (1.4-fold) and the reinternalization of this transporter with the cessation of muscle contraction (Fig. 3) (44). All this was highly reminiscent of contraction-stimulated GLUT4 translocation and glucose transport described a decade earlier (for review, see Ref. 362). Since the contraction-induced fatty acid transport was inhibited by the specific CD36 inhibitor SSO, which binds covalently to CD36 (44, 92, 153), a central physiological role for this fatty acid transporter was established (Fig. 4).

In subsequent studies in cardiac myocytes, it was also shown that contraction induced the translocation of CD36 from an endosomal depot to the plasma membrane (277). Since these initial studies, others have confirmed that contractile activity increases fatty acid transport via the translocation of CD36 in skeletal muscle (443). Contraction can also induce the translocation of FABPpm in skeletal muscle (164, 219), as can AICAR-induced AMPK activation in the heart (73). In addition, studies in cell lines have confirmed, using cell surface labeling techniques, that CD36 translocation is a rapid and reversible process (118, 325, 460). Recently, we have also found that muscle contraction increases the content of FATP1 and FATP4 at the plasma membrane, while plasmaemmal FATP6 is not altered (219). Nevertheless, CD36 is fundamental to facilitating the increase in fatty acid transport, since the contraction- or oligomycin-induced increase in fatty acid transport rate is completely blunted in skeletal muscle (44, 199, 219) and cardiac myocytes (153) by SSO and by sulfo-N-succinimidylpalmitate (SSP), another specific inhibitor of CD36. Moreover, contraction-induced fatty acid transport is lost in cardiac myocytes from CD36 knockout mice (153) and is only minimally increased by the contraction mimetic agent caffeine in muscles of CD36 knockout mice (J. Lally and A. Bonen, unpublished data). These latter studies on CD36 knockout mice have also revealed that the reactive fatty acid esters (SSO, SSP) do not exert nonspecific inhibitory effects on other fatty acid transporters or on protein-independent fatty acid uptake.

The portion of CD36 that is stored in intracellular compartments is estimated to be ~50% both in skeletal muscle (44) and heart (281). This intracellular CD36 depot was found to be enriched within subcellular fractions containing GLUT4 and the transferrin receptor, an endosomal protein (44). Hence, just like GLUT4, CD36 appears to recycle between endosomes and the sarcolemma. However, one report failed to observe an intracellular CD36 depot in human muscle (464). This observation appears to be anomalous, as it is not supported by another similar microscopic study in human muscle (236) or in the many subcellular fractionation studies in humans (18, 48) and animals (71, 73–76, 164, 219, 272, 273, 277, 278, 282).

To morphologically characterize CD36 translocation without using cell-disrupting procedures, Chinese hamster ovary (CHO) cells stably expressing CD36 were created (460). Immunofluorescence microscopy revealed...
CD36 to be located both intracellularly and at the plasma membrane in a punctuate pattern. Upon treatment of these cells with various metabolic stimuli, the punctuate staining of CD36 at the plasma membrane increased by 1.7-fold, indicating the existence of specialized plasmalemmal regions involved in clustering of already present and newly translocated CD36 (460, 461). Whether these CD36 docking regions represent caveoli is uncertain, given the conflicting evidence on the role of caveolins in fatty acid transport (see sect. III D).

Taken together, there is considerable evidence that CD36 is present within an endosomal compartment in muscle and heart. Whether GLUT4 and CD36 are present within the same (presumably) endosomal compartment, or are stored in different subcompartments within the endosomes, awaits further study. Unexpectedly, CD36 docking regions represent caveoli is uncertain, given the conflicting evidence on the role of caveolins in fatty acid transport (see sect. III D).

**FIG. 4.** Similarity between the regulation of cellular uptake of fatty acids and glucose. The uptake of both fatty acids and glucose by cardiac and skeletal muscle is increased after translocation of specific transporter proteins (shown for CD36 and GLUT4, respectively) to the sarcolemma in response to stimulation with insulin or during increased contractile activity. CD36 and GLUT4 may be mobilized from different stores within the endosomal compartment. Note that, for clarity, the involvement of GLUT1 in glucose uptake and the recycling of other fatty acid transporters (FABPs and FATPs) are not shown, while recently it has been observed that they can also be induced to translocate, at least in skeletal muscle (219). FA, (long-chain) fatty acid.

CD36 to be located both intracellularly and at the plasma membrane in a punctuate pattern. Upon treatment of these cells with various metabolic stimuli, the punctuate staining of CD36 at the plasma membrane increased by 1.7-fold, indicating the existence of specialized plasmalemmal regions involved in clustering of already present and newly translocated CD36 (460, 461). Whether these CD36 docking regions represent caveoli is uncertain, given the conflicting evidence on the role of caveolins in fatty acid transport (see sect. III D).

Taken together, there is considerable evidence that CD36 is present within an endosomal compartment in muscle and heart. Whether GLUT4 and CD36 are present within the same (presumably) endosomal compartment, or are stored in different subcompartments within the endosomes, awaits further study. Unexpectedly, CD36 has also been located at the mitochondria where it appears to contribute to regulating fatty acid oxidation (see sect. IV C). Because the mitochondria are not integrated with the recycling compartments encompassing the endosomes, it is very unlikely that mitochondria present a CD36 storage site for translocation to the cell surface. As yet, little is known about the dynamic distribution of other fatty acid transporters between intracellular stores and the plasma membrane.

2. **Endocrine-mediated and pharmacologically induced regulation of fatty acid transport and transporters**

It is well known that the uptake of glucose for cellular energy metabolism is regulated by the reversible translocation of the glucose transporter GLUT4 from endosomal compartments to the sarcolemma in muscle and heart, not only by changes in contraction, but also by insulin and selected pharmacological agents (oligomycin, AICAR, vanadate, arsenite) (24, 265, 267, 277, 282, 440). Recent work in our group and by others has shown that insulin and leptin, as well as the pharmacological agents oligomycin, AICAR, and dipyridamole, induce the translocation of CD36 in skeletal muscle (164, 278, 305) and heart (73, 153, 274, 281, 305, 324). Insulin has also been reported to induce FATP1 translocation in adipocytes (399), but this insulin-induced FATP1 translocation in adipocytes was not observed in another study (346), or in the heart (73, 152). Insulin also failed to induce the trans-
location of FABP_{pm} in heart (73). However, in skeletal muscle, we (219) and others (479) have shown that insulin does induce the translocation of FATP1 (219, 479), as well as FABP_{pm} (164, 219) and FATP4 (219), but not FATP6 (219). These studies indicate that the regulation of translocation of FABP_{pm}, and selected members of the FATP family, but not CD36, appears to be tissue specific.

The recent observation that insulin-stimulated CD36 translocation and fatty acid uptake are additive to contraction-stimulated CD36 translocation and fatty acid uptake (219, 278), just as has been observed for GLUT4 translocation and glucose transport (264), strongly suggests that there are insulin- and contraction-responsive intracellular subcompartments within the recycling endosomes dedicated to CD36 storage, as has previously been shown for skeletal muscle GLUT4 (264). In contrast, the insulin- and contraction-induced increases in plasmalemmal FABP_{pm}, FATP1, and FATP4 are not additive (219), suggesting that unlike CD36, there are no distinct insulin- and contraction-responsive endosomal subcompartments for these transporters.

B. Posttranslational Modification of Fatty Acid Transporters

Subcellular translocation of fatty transporters has been shown to rapidly upregulate fatty acid uptake into (at least) heart and skeletal muscle (see sect. IV.A). Additionally, other posttranslational mechanisms exist that could provide a further level of short-term regulation of fatty acid fluxes. These include palmitoylation, phosphorylation, and ubiquitination of fatty acid transporters. All three possible mechanisms are known to occur within a time scale compatible with short-term regulation.

1. Palmitoylation of fatty acid transporters

Palmitoylation and myristoylation are the two major types of covalent modification of proteins by fatty acids. Whereas protein myristoylation is a cotranslational process and a constitutive type of modification, protein palmitoylation is a short-term inducible event under hormonal regulation. Protein palmitoylation involves a thioester linkage catalyzed by specific protein fatty acyl-transferases and is rapidly reversed by deacylases (25). Moreover, protein palmitoylation is considered important in protein trafficking, especially in targeting proteins to caveolae (149). CD36 has been shown to possess at least two palmitoylation sites, one being a consensus protein kinase C (PKC) phosphorylation site at Thr-92 and one protein kinase A (PKA) phosphorylation site at Ser-237, which are both located within the extracellular loop (Fig. 1B). PKC-mediated CD36 phosphorylation has only been studied in platelets and is involved in determining the ligand specificity of CD36. In resting platelets, CD36 is constitutively phosphorylated and binds mainly to collagen. Platelet activation triggers the release of alkaline phosphatase, which leads to dephosphorylation of CD36, accompanied by a loss of collagen binding to CD36 and an increase in thrombospondin binding (13). However, the role of CD36-Thr-92 phosphorylation in fatty acid transport has not yet been examined. In contrast, the Ser-237 site has been associated with the regulation of the transport activity of CD36. In platelets, CD36-Ser-237 is phosphorylated by a cAMP-dependent ectokinase present at the surface of platelets (177) when these platelets are short-term incubated with cAMP and ATP. This CD36-Ser-237 phosphorylation has been shown to modestly inhibit fatty acid uptake by human platelets (151). However, the functional significance of these findings is not yet clear because it is not known whether there are physiological conditions where cAMP and ATP are simultaneously present at the outer surface of the platelets. Moreover, whether ecto-PKA activity can regulate fatty acid uptake in cells other than platelets is also not known. Finally, to date, regulation of FABP_{pm} and FATPs by phosphorylation has not been reported.

2. Phosphorylation of fatty acid transporters

Protein phosphorylation is not only involved in rapid alterations in enzymatic activity of, for instance, protein kinases, but also in altering the intrinsic transport activity of membrane transporters, such as the L-type calcium channel (453). CD36 has been shown to possess at least two phosphorylation sites, one being a consensus protein kinase C (PKC) phosphorylation site at Thr-92 and one protein kinase A (PKA) phosphorylation site at Ser-237, which are both located within the extracellular loop (Fig. 1B). PKC-mediated CD36 phosphorylation has only been studied in platelets and is involved in determining the ligand specificity of CD36. In resting platelets, CD36 is constitutively phosphorylated and binds mainly to collagen. Platelet activation triggers the release of alkaline phosphatase, which leads to dephosphorylation of CD36, accompanied by a loss of collagen binding to CD36 and an increase in thrombospondin binding (13). However, the role of CD36-Thr-92 phosphorylation in fatty acid transport has not yet been examined. In contrast, the Ser-237 site has been associated with the regulation of the transport activity of CD36. In platelets, CD36-Ser-237 is phosphorylated by a cAMP-dependent ectokinase present at the surface of platelets (177) when these platelets are short-term incubated with cAMP and ATP. This CD36-Ser-237 phosphorylation has been shown to modestly inhibit fatty acid uptake by human platelets (151). However, the functional significance of these findings is not yet clear because it is not known whether there are physiological conditions where cAMP and ATP are simultaneously present at the outer surface of the platelets. Moreover, whether ecto-PKA activity can regulate fatty acid uptake in cells other than platelets is also not known. Finally, to date, regulation of FABP_{pm} and FATPs by phosphorylation has not been reported.

3. Ubiquitination of fatty acid transporters

Covalent linkage of proteins to ubiquitin, a 76-amino acid peptide, is a regulatory posttranslational modification enabling rapid degradation of these proteins. Lysine residues at proteins to be degraded are conjugated to the...
COOH terminus of ubiquitin by the subsequent action of ubiquitin-activating enzymes, ubiquitin-conjugating enzymes, and ubiquitin-protein ligases, after which the protein is targeted for degradation by the proteasome (83). CD36 contains two lysine residues (Lys-469 and Lys-472) within the small intracellular COOH-terminal domain that appear to be major ubiquitination sites. CD36 ubiquitination is under hormonal and nutritional control because treatment of C2C12 muscle cells for 30 min with insulin or fatty acids has been found to inhibit or stimulate ubiquitination of CD36, and thereby prevent or accelerate its degradation, respectively (388). These changes were paralleled by similar changes in fatty acid uptake. Combined with the effects of insulin on CD36 subcellular localization (see sect. IV A), it appears that insulin treatment of myocytes increases sarcolemmal CD36 levels at two different posttranslational mechanisms, i.e., via induction of CD36 translocation to the sarcolemma, and via protection of sarcolemmal CD36 from degradation. Ubiquitination of FABP<sub>pm</sub> and FATPs has not yet been reported.

C. Functioning of Fatty Acid Transporters in Mitochondrial Fatty Acid Utilization

The idea that the rate of fatty acid oxidation by muscle tissues is dictated by the rate of delivery of fatty acids (concentration × blood flow) (155) is undergoing a reassessment. As outlined above, this reevaluation is based on recent experiments showing that fatty acid uptake is regulated at the plasma membrane by the presence of one or more fatty acid transporters. Interestingly, several fatty acid transporters are also present at the mitochondria where they may contribute to regulating fatty acid oxidation in concert with carnitine-palmitoyltransferase (CPT)-I.

1. Fatty acid oxidation

After entering muscle cells, a portion of the fatty acids are activated by acyl-CoAs to long-chain fatty acyl-CoAs in preparation for their import into mitochondria, where they are oxidized to provide ATP for many cellular processes. The CPT system is critically involved in the movement of these fatty acyl-CoAs across the mitochondrial membranes. CPT-I catalyzes the transesterification of fatty acyl-CoA to acyl-L-carnitine. The acyl-L-carnitine can then be translocated to the inner mitochondrial membrane by carnitine:acyl-l-carnitine translocase (CACT), and finally acyl-CoA is regenerated from acyl-L-carnitine by the latent CPT-II within the mitochondrial matrix (240). However, while CPT-I activity is allosterically inhibited by malonyl-CoA (for review, see Refs. 296, 400), the reduction in this malonyl-CoA, and changes in some other regulators, cannot fully account for the CPT-I-mediated increase in fatty acid oxidation that occurs during exercise (31, 317, 318, 356, 402). Thus other processes must also be involved in upregulating fatty acid oxidation in muscle tissues during exercise.

Since it is known that some transport proteins, such as monocarboxylate transporters-1 and -2 (MCT-1 and -2) that transport lactate and pyruvate (21, 481), as well as mAspAT (69), a protein identical to FABP<sub>pm</sub> (26, 69, 217, 419, 485), are present at both the plasma membrane (45, 213, 286) and the mitochondrion (21, 26, 69, 217, 419, 481, 485), it has been suggested that fatty acid transport proteins could also be present in mitochondria, where they could possibly be involved in facilitating the movement of fatty acids into the mitochondria.

2. Mitochondrial FABP<sub>pm</sub>

As noted above, FABP<sub>pm</sub> and mAspAT are identical proteins (see sect. IV A). Transfecting 3T3 fibroblasts (217) or rat skeletal muscle (85, 200) with mAspAT cDNA increased the content of plasmalemmal FABP<sub>pm</sub> and the rate of fatty acid transport into 3T3 fibroblasts (217) and skeletal muscle (85, 200). Concurrently, mitochondrial FABP<sub>pm</sub> was also increased. However, this failed to alter fatty acid oxidation in isolated mitochondria (200). Instead, mAspAT activity increased in proportion to its mitochondrial overexpression (r = 0.75) (200). Thus it appears that FABP<sub>pm</sub>/mAspAT has two distinct functions depending on its subcellular location: 1) at the plasma membrane FABP<sub>pm</sub> contributes to fatty acid transport across the plasma membrane, but 2) at the mitochondrion mAspAT is involved in NADH transport across mitochondrial membranes (200).

3. Mitochondrial CD36 and FATP1

Studies in rat (64, 197, 200, 379, 481) and human muscle (30, 198, 200, 203, 372) have shown that CD36 (30, 64, 197, 198, 200, 203, 372, 481) and FATP1 (379) are present at both the plasma membrane and the mitochondrion. In addition, in skeletal muscle, CPT-I coimmunoprecipitated with CD36 (64, 197, 198, 200, 203, 372, 481) and FATP1 (379). Thus it appears that CD36 and CPT-I, and FATP1 and CPT-I, could be involved in regulating mitochondrial fatty acid oxidation. Evidence for this was reported in L6E9 myotubes in which overexpression of mitochondrial CD36 or FATP1 increased fatty acid oxidation (379).

Similar studies have yet to be performed in mammalian muscle. Nevertheless, strong support for a role of CD36 in skeletal muscle mitochondrial fatty acid oxidation has been shown in a number of studies. For example, there is a high correlation between the rate of palmitate oxidation in isolated mitochondria and the combined effects of mitochondrial CPT-I activity and CD36 content (i.e., multiple regression, R = 0.90) (30). Further support came from studies in which rat muscles were induced to contract by electrical stimulation (30 min) (64) or by
exercise (2 h bicycle ergometry) (198). Mitochondria isolated from these muscles showed an increase in the content of CD36 (64, 198), which correlated with an increased rate of mitochondrial fatty acid oxidation \((r = 0.63)\) in human muscle (198). These data suggest that CD36 translocates from an as yet unidentified CD36 storage compartment to the mitochondria. It remains to be determined whether the recycling endosomes, the intracellular storage pool for sarcolemmal CD36 (see sect. \(\pi A\)), might also provide a storage compartment for mitochondrial CD36.

Further human studies showed that there was a good correlation between mitochondrial CD36 and mitochondrial fatty acid oxidation in lean and obese women \((r = 0.67)\), independent of body mass index (BMI) (203). Increasing skeletal muscle CD36 protein expression, either by chronic muscle stimulation in rats (7 days) (64) or with a program of weight loss and exercise training in humans (372), concomitantly increased fatty acid oxidation and mitochondrial CD36. Moreover, the increased rate of whole body fatty acid oxidation was correlated with an increase in the CD36 associated with CPT-I \((r = 0.93)\), but not with CPT-I alone \((r = 0.16)\) (372). Further support for the involvement of CD36 with regulating mitochondrial fatty acid oxidation came from studies with SSO, a specific blocker of plasmalemmal CD36 (153, 334) (see sect. \(\pi A\)). This CD36 inhibitor reduced fatty acid oxidation by \(>80\)% in mitochondria obtained from both resting and exercised skeletal muscle (30, 64, 198), although more recent work has found that SSO is not CD36 specific in mitochondria (199, 248). Because of this, the contribution of CD36 in the regulation of mitochondrial fatty acid oxidation has been questioned (248). In contrast, we (199) and others (379) do observe a role for CD36 in mitochondrial fatty acid oxidation. Specifically, 1) in CD36 null mice there is a reduced capacity for mitochondrial fatty acid oxidation in resting muscle and a sharply diminished ability to increase mitochondrial fatty acid oxidation in response to muscle contraction (199), 2) overexpressing mitochondrial CD36 in L6E9 myotubes increased the rates of fatty acid oxidation (379), and 3) mitochondrial fatty acid oxidation and mitochondrial CD36, but not CPT-I, are increased in muscle of obese Zucker rats (199). Taken together, there is strong evidence to suggest that CD36 and possibly FATP1 are involved, along with CPT-I, in regulating mitochondrial fatty acid oxidation.

It is questionable whether in mammalian muscle FATP1 is as effective as CD36 in regulating fatty acid metabolism. Presently, it is not known whether FATP1, like CD36, is induced to translocate to the mitochondrion, when muscle metabolic demand is increased. Moreover, recent work has shown that under basal conditions FATP1 has 1) a considerably lower fatty acid transport capacity and 2) a much lower stimulatory effect on fatty acid oxidation than CD36 in intact muscle (315). This may suggest that CD36 is likely more important than FATP1 in contributing to the regulation of mitochondrial fatty acid oxidation.

The mechanism(s) by which CD36 in combination with CPT-I contributes to the regulation of mitochondrial fatty acid oxidation is still unclear. We speculate that mitochondrial CD36 could perform a function that mirrors that of plasmalemmal CD36. Namely, upon cellular fatty acid uptake, plasmalemmal CD36 donates the fatty acids to FABPc, the vehicle for cytoplasmic fatty acid storage and transport to, among others, the mitochondria (142). This transfer of fatty acids most likely involves a direct interaction between CD36 and FABPc (396). Conversely, mitochondrial CD36 could facilitate the unloading of FABPc by accepting the fatty acids for transfer to ACS for activation.

Given that CD36 can be induced to translocate to both the plasma membrane and to the mitochondria, it appears that the rate of fatty acid oxidation is not solely dependent on the rate of fatty acid delivery \((\text{concentration} \times \text{blood flow})\) to the muscle tissues, as has long been thought, particularly during exercise (155). We are now proposing an alternate model for upregulating skeletal muscle fatty acid oxidation, one that involves the muscle contraction-induced subcellular trafficking of CD36. Specifically, the proposed model (201) is a highly regulated and coordinated two-site system that responds rapidly to the muscles’ metabolic needs to increase fatty acid oxidation during exercise. In this model muscle contraction or exercise 1) induces the translocation of CD36 to the plasma membrane, thereby increasing fatty acid uptake into the muscle cell (see sect. \(\pi A\)), and 2) induces the translocation of CD36 to the mitochondrion, where it interacts with CPT-I to increase fatty acid uptake into the mitochondrial matrix to be oxidized (see above). This scheme does not imply that 1) other fatty acid transporters are not involved and 2) an increased delivery of fatty acids via the circulation is unimportant. Rather, this proposed model provides a means whereby intracellular signals initiated by muscle contraction can very rapidly (minutes) to regulate the increase in energy supply into the tissue towards the site of ATP synthesis so as to meet the increased metabolic demands.

D. Coordinated Functioning of Fatty Acid Transporters

It is conceivable that rapid fluctuations in metabolic needs of the heart and skeletal muscle require a distinct mechanism for fatty acid uptake, one that is different from the system that supports fatty acid entry, or release, from adipose cells. The possibility that selected fatty acid transporter proteins might function in a coordinated manner was suggested in the previous decade (142, 143, 286), and there is some experimental support for this idea.
Studies in skeletal muscle and cardiac myocytes have shown that fatty acid uptake was blocked independently, by inhibitors of CD36 and FABP pm, but their effects were not additive (286), suggesting that these two proteins interact with each other to take up fatty acids. Support for this has also been found in other studies. For example, the insulin- and AICAR-stimulated increases in fatty acid uptake did not correlate well with only plasmalemmal CD36 or with only plasmalemmal FABP pm. Instead, the rate of fatty acid uptake was linearly related to the sum of plasmalemmal CD36 and plasmalemmal FABP pm (75). A similar observation occurred in heart and muscle of type 1 diabetic rats (272). Thus there is enticing evidence to suggest that FABP pm and CD36 may interact with each other. In addition, CD36 and caveolin-1 might interact with each other (see sect. III B). Whether any of these latter proteins also interacts with FATPs is unknown, although this may occur as CD36 and FATP6 colocalize in the heart (139). As noted in section IV B, a concerted action among membrane fatty acid transporters, and other proteins such as cytoplasmic FABP (143, 396) and ACS-1 (279, 346), may allow a fine-tuning of fatty acid transport so as to have this substrate readily available for intracellular utilization.

E. Do Fatty Acid Transporters Channel Fatty Acids to a Particular Metabolic Fate?

It has been suggested, based on the overexpression of fatty acid transporters in different cell lines, that specific transport proteins interact with specific intracellular proteins to channel fatty acids to different metabolic fates within the cell (20, 136, 176, 346, 487). Some evidence was recently shown for this in 3T3-L1 adipocytes, in which FATP1 and ACS1 communoprecipitate (346). Overexpression of ACS1 increased the rate of fatty acid transport, leading to the conclusion that constitutive interaction between FATP1 and ACS1 contributes to the efficient cellular uptake of fatty acids in adipocytes through vectorial acylation. This led to the suggestion that fatty acid esterification might be required to stimulate fatty acid uptake into adipocytes (346). Others have shown a role for ACS1, -4, and -6 in contributing to fatty acid transport (432). However, as reviewed above, fatty acid transport is not dependent on activation by ACS1, but, in vivo, these two processes (fatty acid transport and activation) are likely complementary (see sect. III C).

While fatty acid channeling via different fatty acid transporters to different intracellular fates is an attractive hypothesis to account for the large number of fatty acid transporters expressed in a number of tissues, supporting evidence is only available from studies in vitro, in selected cell lines in which normal physiological regulation is largely absent. Moreover, unlike skeletal muscle and the heart, very rapid adjustments in fatty acid provision are not required in quiescent cells with a low metabolic rate.

In vivo, fatty acid channeling to a particular metabolic fate via specific fatty acid transporters would not seem to hold, particularly in metabolically dynamic tissues such as heart and skeletal muscle. Such a scheme ignores the important role of physiological signals such as hormones (insulin) and muscle contraction. Each of these stimuli can induce the translocation of FABP pm, CD36, FATP1, and FATP4 (219), thereby increasing the rate of fatty acid uptake. Following their uptake, the fate of these transported fatty acids is most likely regulated by insulin-specific and contraction-specific intracellular signals that direct fatty acids to esterification or oxidation, respectively, consistent with the metabolic needs of the tissue. Specifically, the contraction-induced increases in the sarcoclemmal pool of CD36 (see sect. IV A) are linked with enhanced fatty acid oxidation (44, 213, 277, 290, 305), and the insulin-induced increases in sarcoclemmal CD36 with enhanced fatty acid esterification (278, 281). Observations in CD36 knockout animals further underscore this notion, as in AICAR-stimulated muscles CD36 ablation selectively impairs fatty acid oxidation while in insulin-stimulated muscles CD36 ablation results in a selective reduction of fatty acid esterification (42). In line with this, pharmacological blockade of CD36 in cardiomyocytes (287) or ablation of CD36 in muscle (42) in the absence of metabolic stimuli reduces basal rates of both muscle fatty acid uptake, esterification, and oxidation to the same extent, indicating that sarcoclemmal CD36 does not channel fatty acids specifically into oxidation or esterification. Together, these observations strongly indicate that the metabolic machinery rather than sarcoclemmal CD36 per se determines the ultimate intracellular metabolic fate of incoming fatty acids.

The metabolic fate of fatty acids that have been transported into heart and muscle is dictated by intracellular signals, fashioned by the energetic demands, i.e., contractile activity (112, 277, 385, 386) and/or the endocrine milieu (e.g., insulin and leptin; Refs. 115, 278, 281, 309, 310, 405). For contractile activity and leptin, the intracellular signal is AMP-kinase activation, which exerts an inhibitory phosphorylation of acetyl-CoA carboxylase, thereby lowering the intracellular malonyl-CoA concentration. Consequently, CPT-I becomes deinhibited, allowing the mitochondrial β-oxidation rate to increase (270, 400). With respect to insulin, this anabolic hormone has been found, at least in adipocytes, to acutely upregulate the activity of glycerol-3-phosphate acyltransferase (GPAT; the rate-limiting enzyme in triacylglycerol synthesis) (462), likely through phosphorylation within a consensus motif for casein kinase-2 (56), a known protein kinase target of insulin signaling (247). Whether recruitment of other fatty acid transporters and/or members of the ACS family respond differentially to these stimuli to act in concert with CD36...
possibly to channel fatty acids to different fates is not known.

In summary, translocation of fatty acid transporters provides a very rapid, localized regulation of lipid metabolism at the level of the plasma membrane. In contracting muscles we propose that this may be accomplished by coordinating fatty acid uptake and mitochondrial oxidation via translocation of CD36 to these subcellular locations at the same time. Cofunctioning of fatty acid transporters at the plasma membrane has been shown and may also occur at other subcellular locations, such as mitochondria. Additional levels of regulation may exist, including possibly ectophosphorylation of CD36 to diminish fatty acid uptake, as has been shown in human platelets (151), CD36 palmitoylation (427), and association with specific membrane microdomains such as lipid rafts (117). Channeling of fatty acids to a particular metabolic fate within the muscle cells, in vivo, is likely directed by intracellular metabolic signals generated by muscle contraction or the endocrine milieu, and may involve selective recruitment of one or more fatty acid transporters and/or members of the ACS family depending on the physiological signal (e.g., contraction or hormones).

V. SIGNALING AND TRAFFICKING EVENTS
REGULATING MEMBRANE TRANSPORTER TRANSLOCATION

In the previous section it was outlined that fatty acid uptake is regulated by a translocation of fatty acid transporters from intracellular stores to the sarcolemma. Hence, the sarcolemmal presence of these transporters is not fixed, but can be altered dynamically in coordination with the continuously changing metabolic demands of heart and muscle.

CD36 and FABPpm are examples of proteins, with cell surface-related functions (receptors and transporters), that recycle to and from the sarcolemma. Even under basal, nonstimulated conditions (low metabolic demand) and consequently a low fatty acid uptake rate, there is no static distribution of fatty acid transporters, but instead a continuous recycling between the endosomal compartment and the sarcolemma in such a manner that the combined rates of endocytosis and exocytosis result in a low basal surface localization (for review, see Ref. 276). Theoretically, increased exocytosis or decreased endocytosis could result in net transporter relocation. From extensive research on GLUT4 translocation in adipocytes, it would seem that a net transporter redistribution to the sarcolemma upon exposure of cardiac tissue or cells to a given stimulus is caused by an increase in the rate of exocytosis without any change in the rate of endocytosis (which is regarded as noninducible in this translocation model). This is currently the most favored view of the regulation of transporter translocation (207, 365, 428), although a decreased endocytosis may also contribute to net GLUT4 translocation (263). Nevertheless, in general, endocytosis is regarded as an unregulatable (housekeeping) trafficking event, while in contrast exocytosis is highly inducible.

Conceptually, the events regulating the net translocation of a given recycling protein, i.e., CD36, can be subdivided into 1) stimulus-induced signaling and 2) induction of trafficking processes, presumably acting on acceleration of exocytosis (Fig. 5). The signaling events can be induced by various mechanical, hormonal, or pharmacological stimuli (see sect. IV.A). Each of these stimuli will induce the activation of key/master protein kinases, which initiate a pleiotrophy of signaling cascades, allowing cells to perform the full range of responses needed to adequately respond to changing metabolic conditions. With respect to regulation of subcellular transporter distribution, one (or more) of these stimulus-induced signaling cascades will activate the vesicular trafficking machinery, thereby modulating the continuous recycling of membrane receptors and transporters to achieve a net translocation of these proteins.

A. Signaling Pathways

Insulin and contraction are the main physiological stimuli able to induce fatty acid uptake through translocation of CD36 and/or FABPpm, as well as FATP1 and -4. Both stimuli activate distinct signaling cascades. Whereas the insulin-signaling cascade starts from the extracellular leaflet of the sarcolemma, the origin of the contraction signaling cascade is intracellular.

I. Insulin signaling

The components involved in the postreceptor insulin signaling pathway, that induce GLUT4 translocation to stimulate glucose transport, are well known and have been the topic of extensive research during the last two decades. This signaling pathway may also be involved in insulin-stimulated fatty acid transporter translocation. Therefore, we briefly review below the sequence of signaling events involved in insulin-stimulated GLUT4 translocation, as a framework for examining insulin-stimulated fatty acid transporter (particularly CD36) translocation.

A) INSULIN SIGNALING PATHWAYS IN GLUT4 TRANSLLOCATION. The binding of insulin to the α-subunit of the insulin receptor induces a conformational change throughout the whole protein, resulting in the autophosphorylation of the receptor β-subunit at tyrosine residues, thereby providing docking sites for phosphotyrosine-binding (PTB) domain containing proteins, most critically the insulin receptor substrates (IRS), of which IRS-1 is the key player in muscle and the heart. In addition, members of the class 1 phosphatidylinositol-3 kinases (PI3Ks) are activated by
the binding of its p85 regulatory subunit to the phosphorylated IRS-1, thereby recruiting PI3K to the plasma membrane. PI3Ks form a family of enzymes phosphorylating the D-3 position on the inositol ring in phosphoinositides, and class 1 PI3Ks specifically convert phosphatidylinositol 4,5-bisphosphate into phosphatidylinositol 3,4,5-trisphosphate (PIP$_3$) for downstream activation of insulin signaling. Investigations on the involvement of

**FIG. 5.** Trafficking pathways involved in CD36 recycling. The transition of CD36 from the endosomal storage compartment to the plasma membrane, and vice versa, is regulated by several protein families with different functions. 1. Bottom inset: adaptor proteins and Rab-GTPases regulate the binding of coat proteins to areas enriched in CD36. The formation of coat complexes leads to the generation of a CD36 transport vesicle which is released to the cytoplasm by scission proteins. After budding of the vesicle, the adaptor and coat proteins again detach. 2: Upon binding of a motor protein, the transport vesicle is moved along cytoskeleton filaments to its designated target membrane. Also this process is initiated by Rab-GTPases. 3. Top inset: tethering proteins trap the transport vesicle below the cell surface. The interaction of a specific subset of vesicle-associated SNAREs (v-SNAREs) and target-membrane associated SNAREs (t-SNAREs) brings the vesicle to such a close proximity to the plasma membrane that the water barrier can be overridden and fusion of the two membranes can occur. After fusion, the SNARE complex disintegrates. 4–6: The transport of CD36 from the plasma membrane to the endosomal compartment proceeds analogous to steps 1–3.
PKC in GLUT4 translocation have been greatly facilitated by the use of pharmacological inhibitors, such as wortmannin and LY294002. Numerous publications report that both inhibitors largely abolish insulin-induced GLUT4 translocation and glucose uptake (for review, see Ref. 381).

The lipid signaling intermediate PIP_3 is not only regulated by its PI3K-mediated formation, but also by its degradation rate by inositol phosphatases, namely, SH2 domain-containing 5′-inositol phosphatase (SHIP)-2, and the tumor suppressor gene product PTEN (phosphatase and tensin homolog deleted on chromosome 10), dephosphorylating PIP_3 at the 3′ position. Hence, these inositol phosphatases are involved in the regulation of GLUT4 translocation (368, 426). The formation of PIP_3 at the plasma membrane directly drives the activation of a number of different protein kinases with lipid binding domains, of which three have now been recognized as essential players in insulin-induced glucose uptake, namely, Akt/protein kinase B (PKB), PKC-ζ, and 3-phosphoinositide-dependent protein kinase-1 (PDK1). Binding of PIP_3 induces a conformational change within these kinases resulting in their autophosphorylation or plasma membrane binding.

The importance of Akt, especially isoform 2, in the regulation of glucose uptake has been revealed in Akt2 null mice (81, 137). The activation of Akt is complex in that it requires dual phosphorylation at Ser-473 and Thr-309 in addition to its PI3K-mediated recruitment to the plasma membrane. The Thr-309 phosphorylation within the activation loop is mediated by PDK1 (9), in which involvement in cardiac insulin-stimulated glucose uptake was subsequently demonstrated by the inability of cardiac myocytes from muscle-specific PDK1 null mice to increase glucose uptake upon insulin treatment (306).

In parallel to Akt2, PKC-ζ is activated by PDK1, upon unfolding of the pseudosubstrate domain and exposure of the activation loop Thr-410 site (122). The involvement of PKC-λ/ζ in insulin-induced GLUT4 translocation and glucose uptake has been convincingly proven in muscle cell lines expressing dominant-negative mutants (17). The simultaneous and combined activation of Akt2 and PKC-λ/ζ is necessary for insulin-induced GLUT4 translocation in both heart (29) and skeletal muscle (122). Akt is known to activate a great number of substrates involved in a pleiotrophy of anabolic responses. Among these, the phosphorylation of an Akt substrate of 160 kDa (AS160) has been found to be particularly important for GLUT4 translocation (367, 483). Insulin-stimulated phosphorylation of AS160 (IR → IRS1-PK2 → Akt2 → AS160) releases the inhibition on vesicular GLUT4 movement to the plasma membrane, as phosphorylated AS160 can no longer maintain rab proteins in a GDP-bound state. Although PKC-λ/ζ targets involved in insulin-induced GLUT4 translocation have not been examined intensively, it appears that PKC-λ/ζ binds to intracellular GLUT4 compartments upon insulin stimulation and directly phosphorylates the GLUT4 compartment-associated vesicle-associated membrane protein-2 (VAMP2) (52). Hence, Akt2-mediated AS160 phosphorylation, as well as PKC-λ/ζ-mediated VAMP2 phosphorylation, are at the threshold between insulin-induced signaling and trafficking events in the translocation of GLUT4 to the cell surface. Excellent, detailed reviews discussing more fully the insulin-stimulated signaling pathway involved in promoting GLUT4 translocation are available (29, 68).

B) INSULIN SIGNALING PATHWAYS IN FATTY ACID TRANSPORTER TRANSLOCATION. Similarly to insulin-induced GLUT4 translocation, the insulin-induced translocation of fatty acid transporters requires the activation of PI3K. Namely, inhibition of this kinase by either wortmannin or LY294002 inhibited fatty acid uptake and CD36 translocation in cardiac myocytes (281) and skeletal muscle (278). However, it cannot yet be deduced which class of PI3K contributes to insulin-stimulated fatty acid uptake because wortmannin and LY294002 potently inhibit most isoforms (381). Likely, class II PI3Ks can be excluded because isoforms within this class are relatively resistant towards both inhibitors (108). Recent studies in L6 muscle cells and in primary cardiac myocytes using pharmacological inhibitors have found that downstream of PI3K, atypical PKC-ζ, but not PKB/Akt, mediates the effects of insulin on fatty acid uptake (239) via translocation of CD36 (284). In contrast to L6 muscle cells, it does appear, however, that Akt-2 is required in mammalian muscle for insulin-induced fatty acid transport and for the translocation of selected fatty acid transporters. Specifically, we have found that insulin (1) failed to stimulate fatty acid and glucose transport in skeletal muscle of Akt-2 null mice, and (2) failed to induce the translocation of CD36 and FATP1, as well as GLUT4, while the translocation of FABP_{pm} and FATP4 was not impaired (218). These observations indicate that insulin-stimulated GLUT4 translocation and the insulin-stimulated translocation of some fatty acid transporters (CD36 and FATP1) are similarly regulated via the PI3K-Akt2 signaling pathway. It is possible, however, via the use of arsenite, to divorce the translocation of GLUT4 from that of CD36 (282). Similarly, CD36 translocation could be divorced from the translocation of FABP_{pm} and of FATP4 in Akt-2 null mice (218). These observations indicate that insulin signaling pathways for GLUT4 and selected fatty acid transporters can at times diverge, either because signals diverge at some point beyond Akt-2 or different subcellular depots of fatty acid transporters are targeted.

2. Contraction signaling

The metabolic demands of muscle contraction favor the activation of nutrient and stress sensing cascades. Hence, an increase in contractile activity can result in a
rapid rise in the concentration of a number of second messengers in heart and muscle, such as AMP, cAMP, Ca$^{2+}$, and reactive oxygen species (ROS). Together these second messengers activate a complex network of signaling events (353). Among all the protein kinases activated by contraction [e.g., PKA, PKC-δ and -ε, extracellularly regulated protein kinases (ERK)-1 and -2, mitogen-activated protein kinase (MAPK), and Ca$^{2+}$/calmodulin-dependent protein kinases (CaMK)], the activation of AMP-activated protein kinase (AMPK) is known to have a variety of metabolic actions (275, 352), including the stimulation of fatty acid oxidation via the phosphorylation and inactivation of acyl-CoA carboxylase (ACC) and the consequent reduction in malonyl-CoA which releases the inhibitory effects on CPT-I (270, 400). In line with this, we have shown that AMPK plays a crucial role in the location of CD36 (73, 277), and that of FABPpm (73). Importantly, some of the other mentioned contraction-activated kinases are not involved in contraction-induced fatty acid transport, including cAMP-activated PKA (289) and conventional or novel PKCs (288).

Based on the central role of AMPK in contraction-induced fatty acid transport, we will discuss which additional protein kinases could be involved in the AMPK signaling pathway to induce fatty acid transporter translocation. This will necessarily be confined to CD36, as similar details are currently not available for other fatty acid transporters.

A) INVOLVEMENT OF AMPK IN CONTRACTION-INDUCED FATTY ACID UPTAKE. AMPK is a heterotrimeric protein consisting of catalytic (α1, α2) and regulatory (β1, β2, γ1, γ2a, γ2b, γ3) subunits (168, 170). Both AMPKα1 and AMPKα2 are expressed in heart and skeletal muscle, of which AMPKα2 is the predominant subunit (401). Activation of the AMPK complex occurs mainly via AMP by three independent mechanisms: 1) promotion of phosphorylation of Thr-172 within the α-subunit by upstream kinases, 2) allosteric activation of the phosphorylated enzyme, and 3) inhibition of dephosphorylation of Thr-172 by protein phosphatases (171). Under conditions that favor a rapid increase in intracellular AMP, such as during increased contractile activity in muscle (477) or during a period of cardiac ischemia (259), AMPK becomes activated, resulting in the activation of catabolic pathways, such as the increased oxidation of fatty acids (exercise) and glucose (ischemia), and the deactivation of anabolic pathways, such as storage of these substrates (169).

Evidence that AMPK is involved in contraction-induced fatty acid transport comes from the observation that contraction-induced fatty acid uptake is not additive to that of agents able to activate AMPK and increase fatty acid transport. However, it must be recognized that some recent studies have begun to suggest that AMPK is not necessarily essential for the regulation of fatty acid oxidation by AICAR or muscle contraction (116, 357). Nevertheless, AMPK-activating agents, oligomycin (a mitochondrial F$_{1}$F$_{0}$-ATPase inhibitor) and AICAR (a cell-permeable adenosine analog, which is converted intracellularly to ZMP, an AMP analog), induce the translocation of CD36 (73, 277) and FABPpm (73) to the sarcolemma. Because muscle contraction (44) and these contraction-mimetic agents failed to stimulate fatty acid transport, either into skeletal muscle or cardiac myocytes (277) treated with the specific CD36 inhibitor SSO (44, 277), or in cardiac myocytes from CD36 null mice (153), it is evident that AMPK-activated induction of CD36 translocation is largely, if not entirely, responsible for increasing fatty acid transport. More direct evidence for the involvement of AMPK in contraction-induced fatty acid transport was obtained with cardiac myocytes from mice overexpressing an AMPKα2 kinase-dead subunit, since this dominant-negative mutant resulted in a severely reduced activation of both AMPKα1 and AMPKα2, and in a complete abolishment of oligomycin- or AICAR-induced fatty acid uptake (152). Similarly, oligomycin-induced fatty acid uptake was also completely lost in cardiac myocytes from AMPKα2 knockout mice, indicating that in the heart AMPKα2, not AMPKα1, is responsible for contraction-induced fatty acid uptake (152).

In this respect, contraction-induced cardiac fatty acid uptake closely resembled contraction-induced GLUT4 translocation, which was also found to be entirely and selectively dependent on AMPKα2 activation in the heart (152).

Whether the translocation of CD36 and possibly other fatty acid transporters in skeletal muscle is also fully AMPKα2 dependent is questionable. It is now known that during muscle contraction the two α-isoforms (AMPKα1 and AMPKα2) can substitute for each other in terms of activity, which may explain the normal glucose uptake despite the lack of either AMPKα1 or AMPKα2 in genetically altered mice (227). Thus the roles of AMPKα1 or AMPKα2 in promoting fatty acid transporter translocation and fatty acid uptake in skeletal muscle remain to be determined.

B) CONTRACTION SIGNALING UPSTREAM OF AMPK. In the late 1980s, kinase activity towards AMPK-Thr-172 (referred to as AMPKK) was detected as a distinct entity in a partial purification of AMPK from rat liver (67). However, it proved to be difficult in subsequent years to purify the kinase-kinase to homogeneity. Fortunately, independent research in yeast provided important clues in the identification of AMPKK. Namely, Snf1, the yeast homolog of AMPK, is phosphorylated by three kinases (204), and database searches revealed three closely related mammalian kinases, LKB1, CaMKKα, and CaMKKβ (166). LKB1 has a ubiquitous expression pattern in mammalian tissues, whereas the expression of CaMKKs is restricted to brain, and to a lesser extent to muscle tissues (11; and see reviews in Refs. 167, 463). In vivo, LKB1 and CaMKK are each regulated differently. In muscle tissue, CaMKKβ activity is inducible, i.e., by an increase in intracellular Ca$^{2+}$ (179). In contrast, LKB1 is constitutively active (363), but
it can only activate AMPK during conditions when intracellular AMP is increased (e.g., exercise), as AMP binding to AMPK induces a conformational change within the AMPK complex so that Thr-172 becomes accessible to phosphorylation by LKB1 (178). While LKB1 has been shown to be involved in contraction-induced glucose uptake in muscle (364), it is still controversial whether CaMKKβ regulates contraction-stimulated glucose uptake in muscle via AMPK activation (222, 223, 478).

Recently, cardiac myocytes from LKB1 null mice were used to examine oligomycin- and AICAR-stimulated fatty acid uptake (152). These studies demonstrated that the stimulatory effects of each of these AMPK-activating agents on fatty acid uptake and CD36 translocation were lost, indicating that LKB1 is the primary AMPKK involved in this metabolic action. Since AICAR and oligomycin each stimulates fatty acid uptake in a nonadditive manner to contraction (152, 277), the AICAR and oligomycin findings can be extrapolated to contraction, namely, that an LKB1-AMPK signaling axis is necessary for contraction-induced fatty acid uptake via CD36 translocation. In skeletal muscle, the regulation of contraction-induced fatty acid uptake may occur in part via Ca^{2+}-dependent activation of CaMKK and AMPK (343, 344), but whether these signals induced the translocation of one or more fatty acid transporters was not determined.

C) CONTRACTION SIGNALING DOWNSTREAM OF AMPK. To date, close to 20 direct cellular targets of AMPK have been identified (434). This number is expected to grow given the critical role of AMPK in cellular energy homeostasis. A consensus recognition motif has now been identified around the site phosphorylated by AMPK (434). Proteins with these motifs include selected transcription factors and a few signaling proteins, as well as proteins involved in fatty acid and glucose metabolism. One signaling protein in particular stands out, namely, AS160. It is strongly implicated in insulin-induced GLUT4 translocation and is likely also involved in insulin-induced fatty acid transporter translocation, given that its upstream kinase Akt-2 is required for insulin-stimulated fatty acid transport and fatty acid transporter translocation (CD36 and FATP4; Ref. 218; see sect. vA1). Indeed, it is now firmly established that in skeletal muscle AS160 is phosphorylated in vivo both by insulin and by exercise, and in situ by electrically induced muscle contraction as well as by AICAR (68, 257), while AS160 phosphorylation is absent in mice deficient in AMPK signaling (435). It now appears that AS160 is a possible point of convergence for insulin- and contraction-signaling pathways from where trafficking processes are activated for simultaneous GLUT4 and CD36 translocation.

There are also several protein kinases, most notably ERK-1/2 and PKC-ζ, reported to operate in contraction-stimulated glucose uptake in skeletal muscle (79). Interestingly, ERK has also been proposed to be involved in contraction-induced CD36 and fatty acid uptake in skeletal muscle, based on the ability of the ERK inhibitor PD98059 to inhibit these events (345, 443). More recent work indicated that contraction-induced fatty acid uptake may occur in part via Ca^{2+}-independent activation of ERK1/2 (343). Another protein kinase recently identified to be necessary for contraction-induced GLUT4 translocation is protein kinase D-1 (PKD1), which is activated independently from AMPK (288). Whether PKD1 has a role in contraction-induced fatty acid transporter translocation has not yet been assessed.

B. Trafficking Pathways

A sequence of trafficking events resulting in translocation of transporter proteins is initiated once the insulin- or contraction-induced signaling cascades have been completed. The cellular machinery responsible for migration of cargo from one compartment to the other, and vice versa, is referred to as the trafficking machinery. Regulation of this transport needs to be unidirectional and extremely specific to ensure that vesicles containing cargo (e.g., CD36 and/or GLUT4) destined for the plasma membrane do not fuse randomly with membranes from other organelles (99). To provide the unidirectionality of intracellular transport, and the proper sorting mechanisms, each mammalian cell type contains a specific set of trafficking proteins, dedicated to adequately meet this specific function. Derived from research with nerve cells for the secretion of neurotransmitters and adipocytes for the translocation of GLUT4 (99), the list of proteins that make up the cellular trafficking machinery includes the following (Fig. 5).

1. SNARE proteins

Soluble N-ethylmaleimide attachment protein receptor (SNARE) proteins are responsible for safeguarding the specificity of the transport of intracellular membrane vesicles according to the principles of the so-called SNARE hypothesis (99). This hypothesis postulates that in vesicular trafficking events a unique vesicle-associated protein (v-SNARE) specifically recognizes and interacts with a cognate t-SNARE protein localized at the target membrane. This specific interaction results in the formation of a SNARE-pin complex necessary for the fusion of vesicles with their target compartments.

2. Rab proteins

Ras-related Rab GTP-binding proteins bind and hydrolyze GTP. In their cycling between GTP-bound (active) and GDP-bound (inactive) conformations, these proteins act as molecular switches in vesicular trafficking (102). Although Rabs have not been detected in the SNARE
complex, they are probably required for the assembly of this complex, as has been shown in yeast (390). Members of the Rab family are associated with distinct intracellular compartments involved in endocytic and exocytic processes, indicating that the individual Rab proteins have specialized transport functions.

3. Coat/scaffolding proteins

Coat proteins are required for the generation of highly curved membranes and the assembly of accessory proteins into a “vesicle fission complex.” Subcellular trafficking vesicles possess characteristic proteinaceous coat structures allowing their classification accordingly into 1) clathrin-coated vesicles, 2) COP-coated vesicles, and 3) caveolin-coated vesicles (caveolae). It is disputed whether these different classes indeed perform different trafficking actions (297).

4. Other proteins

Other proteins involved include motor proteins (dyneins), adaptor proteins for complex formation and cargo assembly (β-arrestin), phosphatidylinositol kinases for generation of bilayer destabilizing phospholipids necessary for vesicle budding, GTPases involved in vesicle fission (ARFs), uncoating proteins (auxillin), filamentous proteins providing the “highway” along which the substrate transporter-containing vesicle travels to the cell surface (297).

Below we summarize the as yet limited information currently available on the involvement of some of these proteins in the regulation of fatty acid transporters, as this Rab member is associated with the insulin-responsive GLUT4 storage compartment (431), which is devoid of CD36 (see sect. IV). A) SNARE PROTEINS. In muscle tissues, insulin-induced GLUT4 translocation is the most intensively studied process in relation to SNARE proteins. In these tissues, vesicle-associated membrane protein-2 (VAMP-2) appeared to be the v-SNARE involved, and syntaxin-4 the cognate t-SNARE, which operates in conjunction with the SNARE-related protein SNAP-23 (for review, see Refs. 127, 397). siRNA experiments have indicated that GLUT4 exocytosis induced by hyperosmolarity (a PI3K-independent stimulus) is not mediated by VAMP-2, but by VAMP-7, and that VAMP-8 is responsible for GLUT4 endocytosis (475). It is not yet known whether these same SNARE proteins are involved in fatty acid transporter translocation, and whether insulin-induced CD36 translocation requires identical or different SNAREs compared with contraction-induced translocation of CD36 or FABPpm. However, the involvement of PKC-ζ in insulin-stimulated fatty acid uptake (possibly through CD36 translocation) might suggest that VAMP-2 is involved in insulin-induced CD36 translocation similar to its involvement in insulin-induced GLUT4 translocation. Namely, VAMP-2 is recognized as a direct phosphorylation target of PKC-ζ (see sect. IV).

B) RAB PROTEINS. In muscle cells and adipocytes, at least three species of Rab proteins were found to be involved in the regulation of GLUT4 translocation: Rab 4 and Rab11 in insulin-stimulated GLUT4 exocytosis (109, 449), and Rab 5 in GLUT4 endocytosis (206). Accordingly, Rab5 has been localized to the cell surface (60, 439). Interestingly, Rab4 and Rab11 seem to be differentially localized: Rab4 is predominantly localized in a specialized insulin-responsive preendosomal compartment uniquely dedicated to the storage of GLUT4 (452), whereas Rab11 specifically associates with recycling endosomes in mammalian cell lines (392, 450). Both intracellular compartments are known to participate in trafficking of GLUT4 in muscle (8).

Only Rab11 has been found to participate in the regulation of trafficking of fatty acid transporters. First, Rab11 was found to be present in intracellular CD36 vesicles (308). Second, silencing of Rab11 in H9c2 cells increased basal cell surface content of CD36 (and GLUT4) (377). Since silencing of Rab11 did not alter the stimulus-induced translocation of CD36, it appears that Rab11 has a role in endocytotic rather than in exocytotic processes (377). This latter study provided the first functional evidence for the role of Rab proteins in CD36 trafficking. Moreover, Rab11 appears to play a similar role in GLUT4 and CD36 translocation. Whether the role of Rab5 in GLUT4 translocation could be extrapolated to the translocation of CD36 or other fatty acid transporters remains to be determined. It is, however, unlikely that Rab4 is involved in translocation of fatty acid transporters, as this Rab member is associated with the insulin-responsive GLUT4 storage compartment (431), which is devoid of CD36 (see sect. IV).

C) COAT PROTEINS. Essentially nothing is known about the involvement of coat proteins in CD36 trafficking, except that caveolin-3 has been colocalized with CD36 at the sarcolemma (236, 464). Its stimulatory role, if any, in fatty acid uptake has already been discussed (see sect. IV). Another mechanism by which caveolin-3 could be positively involved in fatty acid uptake is that it clusters t-SNARE proteins at the cell surface and, as a result, could form a docking station for CD36 vesicles. This, however, remains to be determined.

D) OTHER TRAFFICKING PROTEINS. Adaptor proteins assist in the assembly of coat and SNARE proteins into fission and fusion complexes as well as modulate the function and intracellular localization of Rab proteins. These adaptors also add an extra level of specificity for delivering the cargo to the appropriate subcellular address. It is beyond the scope of this review to discuss the
manner in which all these adaptors are involved in GLUT4 translocation. Generally, the roles of these proteins in the translocation of fatty acid transporters have not yet been assessed, although evidence is beginning to emerge that selected adaptors also function in CD36 translocation. One of these accessory proteins is Munc18c, a member of the Sec1p-like/Munc18 family, which functions in the transition of syntaxins (t-SNAREs) into their open and closed states (111). Munc18c forms a complex with syntaxin-4 (175) and is known to be involved in GLUT4 translocation, as has been shown in cell lines (429) and in skeletal muscle from heterozygous Munc18c knockout mice (319). In cardiac myocytes from heterozygous Munc18c knockout mice, Munc18c appeared to play a similar role in cardiac myocytes from heterozygous Munc18c knockout mice (319). In cardiac myocytes from heterozygous Munc18c knockout mice, Munc18c appeared to play a similar role in GLUT4 translocation, induced by either insulin or AMPK activation, in that a ~50% deletion did not affect fatty acid or glucose uptake induced by each of these metabolic stimuli. Hence, Munc18c appears to be necessary, but not rate-limiting, in cardiac fatty acid and glucose uptake under basal and stimulated conditions (154). In addition, two adaptors for Rab11 have been studied for their role in CD36 recycling (377). Both adaptors belong to a family of Rab11 interacting proteins (FIPs) with a conserved Rab11-binding domain. The first, FIP2, functions as an adaptor for direct interaction of Rab11 with the motor protein myosin Vb (158), and the second, Rip11, colocalizes with Rab11 in endosomal membranes (339). Silencing of FIP2 in H9c2 cells enhanced the surface abundance of both GLUT4 and CD36, while silencing of Rip11 selectively enhanced surface CD36 (377). Hence, Rip11 is normally involved in the intracellular retention of CD36, but not of GLUT4, and this allows Rab11 to discriminate between CD36 and other cargo for trafficking purposes. Interestingly, in adipocytes Rip11 has been reported to be involved in insulin-stimulated GLUT4 translocation possibly through interaction with AS160 (473), indicating that certain trafficking proteins fulfill different roles in different tissues.

Taken together, it is clear that at present the amount of information about signaling and trafficking processes in translocation of fatty acid transporters is at its infancy, yet information about these events is beginning to accumulate. It appears that the trafficking machinery is capable of selectively recruiting fatty acid transporters from either insulin-responsive stores or contraction-responsive stores, through as yet unidentified trafficking proteins that are specifically dedicated to either of these stores. Knowledge about the protein composition of the GLUT4 translocation machinery will provide a framework for examining whether these proteins are also involved in translocation of fatty acid transporters. The identification of novel proteins involved in signaling and trafficking of fatty acid transporters would provide strategies to pharmacologically regulate substrate fluxes. This may be especially important for the treatment of metabolic diseases characterized by altered fatty acid metabolism in heart and skeletal muscle (see sect. viB).

VI. CHRONIC PHYSIOLOGICAL REGULATION OF FATTY ACID TRANSPORTERS

The expression and functioning of the membrane fatty acid transporters is influenced by common physiological stimuli. While in the previous section we focused on acute effects (<30 min), which can alter the subcellular localization of fatty acid transporters, in this section we will discuss our current understanding of the long-term effects, i.e., involving de novo protein synthesis. These long-term effects are mediated by specific transcription factors and coactivators.

Importantly, it should be remembered that proteins, not mRNAs, are the functional unit for physiological processes. The common assumption that fatty acid transporter mRNAs are a suitable index of their protein product is problematic. For example, changes in fatty acid transporter mRNAs frequently do not correlate either with changes in their protein expression or with changes in the rate of fatty acid transport in many experimental models (27, 28, 44, 71, 273, 277, 278, 281, 443, 479), indicating a prominent role for posttranscriptional processes. These studies also illustrate that extrapolation of mRNA data to functional consequences can result in interpretive and conceptual errors. Therefore, it is preferable to examine fatty transporters at the level of their protein expression, although even such data are limiting given that fatty acid transporters can traffic between subcellular compartments (see sect. iv). After all, just as for GLUT4, the functional pools of fatty acid transporters are those at the plasma membrane.

A. Regulation of Fatty Acid Transporter Expression

Like many proteins involved in lipid transport and metabolism, the expression of most, if not all, membrane fatty acid transporters is under the transcriptional control of nuclear peroxisome proliferator-activated receptors (PPAR) in a tissue-specific manner. Depending on the presence of (one or more of) the three PPAR subtypes, α, β/δ, and γ, cells will respond to specific PPAR agonists by transcriptionally upregulating the expression of fatty acid transporters. For instance, synthetic agonists for PPARα (known as fibrates) induce CD36 expression in the heart (19), while CD36 expression is significantly decreased in hearts and muscle of the PPARα null mouse (307). Because PPARγ is expressed in skeletal muscle but virtually
absent in heart (19), CD36 expression was found sensitive to regulation by PPARγ agonists in human skeletal muscle (70) but not in rat cardiac myocytes (454). Fatty acids and selected fatty acid metabolites are the physiological ligands for the PPARs, allowing mammalian cells to upregulate fatty acid transporters and the lipid metabolic machinery in case of increased exposure to fatty acids, so to create a vicious cycle of increased exposure and utilization (for review, see Refs. 291, 398).

While initial studies had concluded that the promoter region of CD36 contains a peroxisome proliferator-responsible element (PPRE) (433), subsequent studies revealed the absence of PPRE in the responding upstream promoter region and showed that transcriptional activation of the CD36 gene by PPAR ligands is indirectly dependent on PPAR (369). This would also explain the delayed transcriptional activation of CD36 expression by PPAR ligands, compared with other PPAR target genes (369). With respect to the other fatty acid transporters, a functional PPRE has been identified in the promoter region of FATP1 (129) and likely is also present in the promoter of the other FATPs. In line with this, PPAR activators were found to coordinate regulate the expression of CD36 and acyl-CoA synthetase in rat tissues (293). The presence of a PPRE in the promoter of FABPpm has not been reported, but is likely as PPARγ activation induced the expression of FABPpm in rat skeletal muscle (22).

More recent studies have disclosed that overexpression of the PPARγ coactivator 1α (PGC-1α) increased the expression of CD36 (23, 82), as well as GLUT4 (23), in rat muscle, together with an increase in mitochondrial fatty acid oxidation (22). Finally, CCAAT/enhancer binding protein α (C/EBPα) was found to regulate CD36 gene expression at the transcriptional level (341), but the role of this transcription factor most likely is restricted to adipocytes, especially during the differentiation of these cells.

Taken together, fatty acids and specific metabolites are now recognized to modulate the expression of multiple genes, notably those involved in fatty acid metabolism, in a PPAR-dependent manner. Fatty acids as signaling molecules thereby “prepare” the cell for the uptake and utilization of larger amounts of fatty acids. Fatty acid transporters take part in this process in a special fashion as they could promote a positive-feedback loop to further increase gene transcription.

B. Effects of Development, Ageing, and Gender

1. Development and ageing

The oxidation capacities and mitochondrial enzymes of heart and muscle increase quickly during development, reaching adult values at 15–20 days postnatally in heart (144) and by 35 days in skeletal muscle (47). A similar rapid adaptation (days 10–35) was observed in CD36 protein expression in rat heart and muscle, while FABPpm protein expression was unaltered in the heart and was reduced somewhat in muscle (47). Thereafter, CD36 expression and mitochondrial enzyme activity remained invariant from 5 to 52 wk (47). The increases in fatty acid transport in the transition from the neonatal period (day 10) to the adult stage was attributable to concomitant increases in plasmalemmal CD36 in heart, and to plasmalemmal CD36 and FABPpm in muscle.

In older rats (15–24 mo vs. 5 mo), fatty acid oxidation was reduced while esterification was increased (441). The concurrent changes in fatty acid transporters were not detailed except to note that FABPpm expression was increased (441). The increased fatty acid transporters were not detailed except to note that FABPpm expression was increased (441). Similarly, in hearts of aged mice (52 wk), there is a twofold increase in intramyocardial lipid accumulation, as well as a ~50% reduction in fatty acid oxidation (254), which is accompanied by a dramatic increase in CD36 (4-fold) in these aged murine hearts compared with young hearts. This suggests that CD36 is a mediator of multiple metabolic, functional, and structural alterations in the aged heart, particularly since hearts from aged CD36 null mice were found to have lower intramyocardial lipid concentrations and enhanced cardiac function compared with the aged wild-type mice (254).

Taken together, it appears that myocardial fatty acid uptake increases to a higher level at both ends of the life span, i.e., perinatally and during ageing, effects that appear to be mediated in part by the upregulation of CD36. While in the neonate the increase in CD36 would seem to be positively associated with the capacity to oxidize fatty acids, it appears that in the aged animals the further upregulation of CD36 allows the uptake of fatty acids to outpace the capacity for fatty acid oxidation. This then leads to deleterious metabolic consequences in heart and muscle of aged animals, which resemble those observed in insulin resistance and type 2 diabetes in which CD36-mediated fatty acid transport also exceeds the capacity for oxidation (see sect. viIB).

2. Gender differences

Fatty acid metabolism has long been suspected to be greater in females than in males. This gender difference has been addressed in a recent review, particularly as it applies to skeletal muscle triacylglycerol esterification and oxidation (242). Although a number of fatty acid transporters are coexpressed in rat and human muscle, including FABPpm, CD36, FATP1, and FATP4 (45, 46, 219, 445), it has been difficult to demonstrate that there are gender differences in fatty acid transporters in skeletal muscle. For example, CD36 protein expression was somewhat higher in women than in men (244), but this was not observed in another study (389). Gender differences have
not been observed in FABP<sub>pm</sub> protein expression or FATP1 mRNA (244, 384). However, there appear to be gender-related sensitivities in CD36 responses to fatty acid infusion, since in male, but not female rats, fatty acid infusion induced insulin resistance and reduced muscle CD36 total protein by 50% (189). Similarly, it has been observed that FABP<sub>pm</sub> protein expression is increased in endurance-trained men but not endurance-trained women (244). Some of these discrepant findings between men and women may be related to difficulty in matching the sexes appropriately and/or the criteria that are employed for matching individuals.

C. Effects of Fasting, Hormones, and Exercise Training

1. Fasting

Several studies have shown that fasting alters fatty acid metabolism in heart and skeletal muscle. For example, short-term fasting (12–48 h) increased FABP<sub>pm</sub> protein at the plasma membrane by 60% (444). Similarly, 48 h of fasting increased CD36 expression in the heart (~2-fold) (455) and in skeletal muscle (~20%). The fasting-induced upregulation of CD36 mRNA and protein, as well as other genes involved in lipid metabolism, is AMPK γ3-dependent (269).

2. Insulin

In cardiac myocytes, insulin not only (acutely) induces the translocation of CD36, but also relatively rapidly (~2 h) increases the expression of CD36 protein, but not FABP<sub>pm</sub> (72). Similarly, CD36 protein content was increased 1.5-fold in human muscle after 3 h of insulin stimulation (94). In the studies in perfused hearts and cardiac myocytes there were similar insulin-induced increments in CD36 protein expression (cardiac myocytes +43%; Langendorff-perfused hearts +32%) and in plasmalemmal protein content (+29%) and rates of fatty acid transport (+34%) (72). Thus CD36 expression is highly responsive to insulin stimulation, although in insulin-resistant individuals with increased circulating concentrations of insulin, only the plasmalemmal content of CD36 expression is increased, not total CD36 protein expression (48).

2. Leptin

It is well documented that leptin acutely increases fatty acid utilization by activating AMPK in skeletal muscle (302, 309, 310, 403–406). Leptin appears to induce the translocation of CD36 from an intracellular depot to the plasma membrane (305, 324), thereby increasing fatty acid uptake and providing the necessary substrate for fatty acid oxidation. In contrast, prolonged leptin infusion (2 wk) downregulated FABP<sub>pm</sub> and CD36 protein expression as well as their plasmalemmal contents in skeletal muscle, resulting in a parallel reduction in fatty acid transport (404). This long-term effect of leptin may have been a compensatory response. Similarly, in adipocytes of ob/ob mice, prolonged leptin treatment (21 days) reduced FABP<sub>pm</sub> and CD36 mRNAs and normalized fatty acid uptake (121). Clearly, leptin exerts profound effects on fatty acid transport and transporters, although the acute and chronic effects of this adipokine differ.

3. Exercise training

Short-term electrically stimulated muscle contraction, and likely also acute volitional exercise, have been described in section iv to stimulate both fatty acid and glucose utilization via translocation of GLUT4, CD36, FABP<sub>pm</sub>, FATP1, and FATP4 (44, 219, 277, 443) but not FATP6 (219) to the plasma membrane. In contrast, it is well known that endurance exercise training shifts fuel selection both at rest and during exercise towards fatty acid oxidation and esterification, as training-induced adaptive responses include increased activity of enzymes involved in fatty acid oxidation and esterification, as well as intramuscular triacylglycerol accumulation (40, 113, 196, 215, 242, 374, 457). Because exercise training does not increase the circulating concentrations of fatty acids, it seems feasible that an increase in fatty acid transport promotes the enhanced capacity for fatty acid metabolism in trained skeletal muscle.

In rats, exercise training failed to alter the expression of either CD36 or FABP<sub>pm</sub> total proteins in the heart despite the fact that fatty acid oxidation was increased (61). This may suggest perhaps that these proteins were redistributed in the cell to increase the plasmalemmal content, as this has previously been shown to account for the increased fatty acid oxidation in murine hearts, in which fatty acid oxidation is markedly increased (65).

Increasing muscle activity with exercise training (447) or 7-day chronic low-frequency stimulation of the peroneal nerve (41, 252) increased both CD36 and FABP<sub>pm</sub> protein expression and their plasma membrane contents, as well as increasing the sarcolemmal transport rate of fatty acids (41, 252, 447). The increase in fatty acid transport (1.9-fold) matched the increase in fatty acid metabolism (1.9-fold, sum of oxidation and esterification) (41). Induction of muscle inactivity (7-day denervation) lowered rates of fatty acid transport, but this was due to a reduction in plasma membrane CD36 and FABP<sub>pm</sub>, while there was no change in their total protein expression levels (252) (Fig. 6). Taken together, these findings indicate that fatty acid transport can be regulated by several mechanisms, i.e., 1) by altering the total protein expression of CD36 and FABP<sub>pm</sub> and their contents at the plasma membrane (exercise training or chronic muscle stimulation), or 2) by altering their
presence at the plasma membrane, without altering protein expression (denervation). Indeed, the functional pool of fatty acid transporters are those at the plasma membrane, since the up- and downregulation in fatty acid transport in chronically stimulated and 7-day denervated muscle correlated highly with the plasmalemmal contents of CD36 and FABP<sub>pm</sub>(252) (Fig. 6).

Exercise training studies in humans have shown variable responses with respect to adaptive changes in the protein expression of CD36 and FABP<sub>pm</sub>. In some studies exercise training has increased CD36 but not FABP<sub>pm</sub> (63% VO<sub>2peak</sub>; Ref. 442). Others have shown, applying a one-leg knee extension training model in which the contralateral muscle serves as control, that FABP<sub>pm</sub> protein expression is increased (CD36 was not measured; Ref. 243). These different effects observed may be exercise-intensity dependent, as with high-intensity exercise training (90% VO<sub>2peak</sub>) there was only an increase in FABP<sub>pm</sub> but not CD36 (423), while with very-high-intensity exercise (>100% VO<sub>2peak</sub>) that is largely dependent on glyco- gen utilization no changes were observed in either CD36 or FABP<sub>pm</sub> protein expression, but increases did occur in other transport proteins (GLUT4, MCT-1 and -4; Ref. 62). Uptregulation of fatty acid transporters CD36 and FABP<sub>pm</sub> may also be influenced by the dietary state during training. For example, providing a high carbohydrate-rich breakfast before training failed to result in any training-induced changes in CD36 and FABP<sub>pm</sub> (100). This contrasted markedly with training in the fasted state, when the demands on fatty acid metabolism are greater, as this increased (~20%) both CD36 and FABP<sub>pm</sub> protein expression coordinately (r = 0.63) (100). It may be important in future studies to determine whether fatty acid transporters have been relocated to the plasma membrane and/or to the mitochondria, in the absence of any changes in their expression. Subcellular relocation of fatty acid transporters without a change in their protein expression have been observed in denervated muscle (see above) (252) and in muscles from obese animals (273) and humans (48) (see sect. VII B).

VII. ALTERATIONS IN FATTY ACID TRANSPORTERS IN DISEASE

In view of the general significance of membrane fatty acid transporters for whole body lipid metabolism and specifically their role in the acute regulation of cellular fatty acid uptake in muscle and heart, it is to be expected that changes in cellular lipid metabolism such as occur in disease states will be accompanied by concomitant adaptations in the expression and/or subcellular location of selected fatty acid transporters. On the other hand, changes in fatty acid transporter content or functioning, as may be caused by nutritional, hormonal, or pharmacological stimuli, will likely have an impact on whole body lipid metabolism. Examples of both such alterations, with a primary focus on heart and muscle, will be discussed in this section. These findings also begin to suggest that membrane fatty acid transporters may be exploited as therapeutic targets.

A. Cardiac Hypoxic Disease and Heart Failure

The heart can use a variety of metabolic substrates to cover its demand for energy, and it has the capacity to rapidly switch among these substrates in response, e.g., to changes in their supply, actions of hormones and cyto- kines, and the availability of oxygen (400). In normal conditions, cardiac metabolic energy is provided from the oxidation of long-chain fatty acids (40–60%), glucose (30–50%), and lactate (10%). In hypoxic conditions, as caused acutely by an ischemic insult or myocardial infarction, the heart switches to the substrate with the highest oxygen efficiency, i.e., carbohydrates, provided from glucose and endogenous cardiac glycogen. During reperfusion, when oxygen supply is reinstated, there is a progressive increase in the contribution of fatty acids to ATP production. In chronic cardiac disease and heart failure, the changes in substrate preference are more permanent and are accompanied by alterations in the expression of metabolic enzymes and proteins. Such chronic changes might influence the so-called metabolic flexibility of the heart, i.e., the ability to switch to other energy substrates and to better withstand an acute metabolic stress (140, 400).

1. Acute changes

The acute switch in substrate utilization that occurs during short-term hypoxia, i.e., an increased contribution...
Fatty Acid Transporters and Lipid Metabolism

During reperfusion following an ischemic insult, there is a shift towards increased fatty acid utilization. Whether CD36 serves a beneficial or detrimental role during this transition has been studied by two groups of investigators. Irie et al. (216) reported that isolated working hearts from CD36 null mice showed a 40% lower postischemic recovery of cardiac function compared with hearts from wild-type littermates. Hearts from mice reexpressing CD36 in heart and skeletal muscle under the muscle creatine kinase promoter showed an ischemic tolerance comparable to that of wild-type hearts, further indicating that the decreased tolerance in CD36 null mice is directly caused by CD36 deficiency (216). Dietary intervention with medium-chain fatty acids to circumvent the CD36-mediated upregulation of fatty acid transporters provide dynamic regulation of substrate uptake and thus add to the metabolic flexibility of the heart.

2. Chronic changes

The development of cardiac hypertrophy and heart failure is associated with changes in cardiac substrate preference, namely, glucose utilization is increased at the expense of fatty acids (10, 400). In the postinfarction rat heart, this change in substrate preference is reflected in an upregulation of GLUT1 and downregulation of genes of lipid metabolic enzymes and of fatty acid transporters (181, 359). Specifically, the myocardial contents of FABP<sub>pm</sub>, CD36, FATP1, and FATP6 protein expression were each reduced with a parallel decrease in palmitate oxidation rate and in cardiac ejection fraction (181). These data suggest that fatty acid transporters may be involved in the transition away from fatty acid metabolism in heart failure, but it should be noted that the subcellular localization of the transporters was not examined in either of these studies.

Likewise, fatty acid transporter deficiency, which will limit cardiac fatty acid utilization and elicit an increase in glucose utilization, is associated with the development of cardiac hypertrophy (216, 313). This parallels the effect of pharmacological inhibition of mitochondrial β-oxidation, which also leads to increased glucose utilization and ultimately to cardiac hypertrophy (54, 360).

![Graph showing changes in substrate utilization in hearts from CD36 null mice. Rates of palmitate oxidation (left), glucose oxidation (middle), and tricarboxylic acid (TCA) cycle acetyl-CoA production (right) were determined in wild-type and CD36 null mouse hearts perfused as working hearts with 1.2 mM palmitate and 5 mM glucose. TCA cycle activity was calculated from the rates of palmitate and glucose oxidation, using 8 mol acetyl-CoA for every 1 mol palmitate oxidized and 2 mol acetyl-CoA for every 1 mol glucose oxidized. The lower palmitate oxidation seen in hearts from CD36 null mice is compensated by an increase in glucose oxidation so that these hearts are not energetically compromised. [Redrawn from Kuang et al. (258), with permission from the American Heart Association.]
For example, CD36 null mice on a regular diet develop cardiac hypertrophy (216, 313), but interestingly, FATP1 null mice do not (up to 15 mo of age) (245). Chronic (12 wk) intraperitoneal administration of SSO, a selective inhibitor of CD36-mediated fatty acid uptake (93, 153), caused cardiac hypertrophy (260). Conversely, aged (>1 yr) mice developed cardiac hypertrophy in the face of a greater than fourfold increase in total myocardial CD36 protein expression in aged animals (254), but in this study neither sarcolemmal CD36 nor fatty acid uptake was determined, hampering the interpretation of the data. Nevertheless, when taken together, the above findings suggest that fatty acid transporters are mediators of substrate-induced cardiac remodeling.

A role for CD36 deficiency in the development of cardiac hypertrophy was suggested from studies with a strain of spontaneously hypertensive (SHR) rats maintained in North America (7, 157). However, it appears that these animals are not CD36 deficient, and fatty acid uptake is not compromised (43) (see sect. viB). Thus cardiac hypertrophy in this model is attributable to other factors.

3. Human studies

There is some evidence to suggest that the link between CD36 expression and cardiac hypertrophy and possibly tolerance to ischemia, as observed in rodent models, can also be extended to humans. A Japanese study revealed that ~40% of patients with hypertrophic cardiomyopathy carry mutations in CD36 leading to a negligible or markedly reduced CD36 protein expression (320, 425). Mutations leading to CD36 deficiency are rare in Caucasian populations (<0.3%), but these are at least 10 times more frequent (3–6%) in Asian, African, and African-American populations (98, 262, 271). These CD36 mutations were shown to lead in almost all cases to severe reductions in myocardial long-chain fatty acid uptake (320, 425), which metabolic change may have triggered the hypertrophic response as seen in the animal studies described above. On the other hand, a subsequent study (424) showed that patients with a total defect in myocardial fatty acid uptake, which in all cases was associated with the absence of CD36, do not always develop hypertrophic cardiomyopathy (424). This latter finding and the broad spectrum of clinical manifestations of hypertrophic cardiomyopathy may explain why another study reported that the incidence of CD36 deficiency in hypertrophic cardiomyopathy patients is not higher than in the general population (311). Clearly, the development of heart disease in humans is complex, and the association between CD36 expression and heart function and failure needs further exploration, whereby special attention should be given to the functional presence of CD36 on the sarcolemma and its association with mitochondria.

B. Insulin Resistance and Type 2 Diabetes

Insulin resistance and type 2 diabetes are associated with changes in lipid metabolism. For example, there is a strong association between skeletal muscle insulin resistance and 1) plasma fatty acid concentrations (36–38) and 2) intramuscular triacylglycerol deposits (220, 221, 256, 326, 409). However, intramuscular triacylglycerol deposits are an indirect marker of insulin resistance, since the more soluble lipid metabolites such as ceramides, diacylglycerols, and long-chain fatty acyl-CoAs interfere with the postreceptor insulin signaling cascade (77, 78, 90, 193, 194, 410, 421). This excessive accumulation of intramyocellular fatty acids and their metabolites has been referred to as lipotoxicity and is a main contributor to the pathophysiology of insulin resistance and dysfunctioning of heart and skeletal muscle (194, 451). The pathological state of the lipid-overloaded, insulin-resistant, and failing heart is commonly referred to as diabetic cardiomyopathy (1, 400). Several recent reviews discuss in detail the defects in postreceptor insulin signaling mechanisms (1, 194, 207, 428) that are at the root of fatty acid-induced insulin resistance in skeletal muscle and the heart in obesity and type 2 diabetes.

Fatty acids that are taken up into heart and skeletal muscle are primarily oxidized or stored as triacylglycerols. As long as the fatty acid uptake and partitioning remains appropriately balanced, metabolic dysregulation does not occur. However, these processes are unbalanced toward lipid accumulation in insulin-resistant skeletal muscle (18, 48, 164) and the heart (322, 380). This increase in intracellular lipid accumulation would not seem to be simply attributable to a concomitant reduction in (mitochondrial) fatty acid oxidation as has been speculated (238), since there is no consistent evidence in support of this notion (for review, see Ref. 195). For example, in heart and skeletal muscles of high fat fed rats, db/db mice, obese Zucker rats, and ZDF rats fatty acid oxidation is either reduced slightly (18, 164, 322), unaltered (387, 482), or increased (65, 66, 91, 446). In muscle from obese humans, a reduction in skeletal muscle fatty acid oxidation is at times observed (202, 210, 246, 430), but not always (48, 405). In individuals with type 2 diabetes, whole muscle fatty acid oxidation also appears to be reduced (18), and basal mitochondrial oxidative phosphorylation was reduced in insulin-resistant offspring of patients with type 2 diabetes (331). In obese individuals, the reduction in fatty acid oxidation appears to be correlated with the extent of obesity (BMI) (430) and has also been attributed to a reduced mitochondrial content (202, 246, 384), as fatty acid oxidation by isolated mitochondria of obese individuals was normal (202) and not impaired as had been suggested previously based on indirect assessment of mitochondrial fatty acid oxidation (237, 355). Similarly, in individuals with type 2 diabetes, reductions
in muscle fatty acid oxidation and oxidative phosphorylation appear to be a result of reduced mitochondrial content, possibly as a result of diminished physical activity, rather than an intrinsic defect in their mitochondria (50, 101, 304, 331, 342), especially since in isolated mitochondria respiratory function, mitochondrial citrate synthase, and β-HAD activities were normal, as was the rate of palmitoyl-L-carnitine oxidation (50, 304). It has been suggested recently that obesity-related insulin resistance in skeletal muscle is associated with an inability of mitochondria to oxidize the excess influx of fatty acids, which leads to an accumulation of intramuscular lipids (255). We (197) have examined this question as described further in section V11.

In conclusion, observations in some studies that mitochondrial fatty acid oxidation may be increased at times suggests that factors other than simply a reduction in fatty acid oxidation can contribute to the intramuscular lipid accumulation, particularly I) an increased delivery of circulating fatty acids, such as is frequently observed in obesity, and/or 2) an increased rate of in fatty acid transport, facilitated by an increase in fatty acid transporters. Importantly, in cases that reductions in fatty acid oxidation in insulin-resistant skeletal muscle were reported, these reductions reflect reductions in mitochondrial content rather than impairments in the intrinsic ability of mitochondria to oxidize fatty acids.

1. Permanent subcellular relocation of fatty acid transporters

A) ANIMAL MODELS OF INSULIN RESISTANCE. Studies examining the rates of fatty acid transport have been performed in animal models of high-fat diet-induced insulin resistance (182, 322), in obese (Zucker obese fa/fa) (197, 273) and type 2 diabetic rats (Zucker diabetic fatty, ZDF) (27, 71, 91), and in murine models of obesity (28, 150). These studies have shown that fatty acid uptake rates were increased in key metabolic tissues, including I) hearts of obese Zucker rats (40–90%; Refs. 27, 91, 273), ZDF rats (120%; Ref. 27), and rats fed a high-fat diet (43% Ref. 322); and 2) skeletal muscle of high fat fed rats (40–80%; Ref. 182), obese Zucker rats (80% Ref. 273), in red but not white muscle of ZDF rats (+66–99%; Ref. 71), and in rats fed a high-sucrose diet during the suckling period (50%; Ref. 211). Thus, in all models of insulin resistance, fatty acid transport is upregulated in heart and skeletal muscle. This upregulation is already present in muscles of 6-wk- old ZDF rats, before the onset of type 2 diabetes (71). It appears that upregulation of fatty acid transport is a predisposing factor to obesity and insulin resistance. However, the underlying mechanisms promoting fatty acid transport appear to differ depending on the severity of insulin resistance (see below).

B) MODEST AND MODERATE INSULIN RESISTANCE. In models of modest (high-fat diet; Refs. 182, 322) to moderate insulin resistance (obese Zucker rats; Refs. 91, 164, 273), the increased rates of fatty acid transport in heart and muscle in general were not related to the increased expression of fatty acid transporter proteins (CD36 and FABPpm) in these tissues (91, 211, 273, 322). However, there was a marked increase in the content of the functional pool of fatty acid transporters, i.e., those at the plasma membrane in heart (CD36, +60–74%; FABPpm, +50%) (91, 273) and in skeletal muscle (CD36, +33–80%; FABPpm, 0–14%) (164, 211, 273). This “permanent relocation” of CD36 to the plasma membrane in skeletal muscle has been confirmed in more recent studies, which also demonstrated that such changes were not observed for plasmalemmal FABPpm, FATP1, and FATP4 (197). Thus these studies have revealed a previously unknown mechanism that increases fatty acid uptake in modest and moderate models of insulin resistance. Specifically, CD36 and FABPpm are permanently relocated from their intracellular depots to the cell surface in heart (91, 273), while in skeletal muscle such a permanent relocation was mainly observed for CD36 only, not FABPpm, FATP1 or FATP4 (164, 197, 273).

C) SEVERE INSULIN RESISTANCE. In ZDF rats, which progress rapidly from insulin resistance (week 6) to severe type 2 diabetes (week 24) (71, 466, 467), there was an increase in the rate of fatty acid transport and the CD36 protein expression and plasmalemmal content compared with age-matched, nondiabetic animals (71). Similarly, in female ZDF rats, which develop diabetes when fed a high-fat diet, there was also an increase in muscle CD36 protein expression and plasmalemmal content (387). However, concurrent treatment with metformin or exercise impaired the increase in CD36 protein expression and plasmalemmal content, and this was associated with reductions (relative to the high-fat diet) in circulating glucose and in intramuscular ceramide and diacylglycerol contents. This study (387) begins to suggest that reducing plasmalemmal CD36 reduces the severity of intramuscular lipid accumulation and hyperglycemia.

D) METABOLIC EFFECTS OF IMPAIRED CD36 TRANSLLOCATION ON FATTY ACID METABOLISM. Presumably, the insulin resistance in CD36 signaling-trafficking accounts, in part, for the inability of insulin to further stimulate triacylglycerol esterification in obese Zucker rat heart and muscle, beyond the already increased rates observed under basal conditions (91, 164). This, however, is not apparent during contraction (muscle) or AMPK activation (heart), as the normal FABPpm translocation (164), along with the already upregulated plasmalemmal CD36 (91, 164), seems to provide the needed fatty acid transport capacity to upregulate fatty acid oxidation rates in obese animals. This begins to imply that an increase in both plasmalemmal CD36 and FABPpm contribute to the upregulation in contraction-
stimulated fatty acid oxidation. Indeed, some tentative preliminary evidence for this has been shown in skeletal muscle into which CD36 and FABP<sub>pm</sub> were cotransfected (314).

2. **Key role of CD36 in insulin resistance**

In the type 2 diabetic heart (db/db mice), the increased expression (+50%) and plasmalemmal content of CD36 (+75%), and possibly the small change in plasmalemmal FABP<sub>pm</sub> (+18%), were positively correlated with the increased rates of fatty acid esterification (~2-fold). All other parameters involved in regulating lipid metabolism (CPT-I activity, CPT-I sensitivity to inhibition by malonyl-CoA, UCP3 expression) were either unaltered or reduced (AMPK activity) (65). This suggests that in rodent models deficient in leptin signaling, alterations in sarcolemmal fatty acid transporters rather than alterations in mitochondrial β-oxidation are responsible for cardiac lipid accumulation and, subsequently, loss of cardiac function.

More direct evidence for the role of CD36 in increased fatty acid esterification and lipid accumulation in the insulin resistant heart was obtained with pharmacological and genetic experiments to block CD36. In cardiac myocytes of high fat fed rats (322) and obese Zucker rats (91), blocking CD36-mediated fatty acid uptake in these insulin-resistant tissues (91, 322), using the specific CD36 inhibitor SSO, lowered the augmented rate of fatty acid esterification. A similar effect occurred when CD36 was ablated in a model of lipotoxic cardiac myopathy (480). This indicates that the upregulation of CD36 at the plasma membrane in insulin resistance is a key factor contributing to the accumulation of intracellular lipids.

A) **TIME COURSE OF CD36 RELOCATION.** As established in the heart and muscle, the permanent CD36 relocation to the plasma membrane is an early event in the development of insulin resistance and cardiomyopathy. Importantly, it has been observed that the increase in CD36-mediated fatty acid uptake in cardiac myocytes precedes changes in glucose uptake. Namely, in cardiac myocytes from insulin-resistant prediabetic obese Zucker rats, CD36 translocation and increased basal fatty acid uptake occurred in the absence of changes in basal and insulin-stimulated glucose uptake (92). Upon the transition from insulin resistance to type 2 diabetes, as seen in high fat fed rats (322) and diabetic Zucker rats (Luiken et al., unpublished results), CD36 translocation and increased basal fatty acid uptake are accompanied by concurrent decreases in basal and insulin-stimulated glucose uptake. Hence, during the development of diabetes there will be an increased juxta-posed localization of CD36 and GLUT4, with CD36 being at the cell surface and GLUT4 being localized intracellularly (Fig. 8). Moreover, it has been known for some time that the insulin-sensitive glucose transporter GLUT4 is retained within the intracellular depot(s) in obese skeletal muscle in animals (57, 58) and in humans (12, 361). The strong inverse relationship [r = −0.91 (71) and r = −0.94 (387)] between plasmalemmal GLUT4 and CD36 in insulin-resistant skeletal muscle in several studies is striking (71, 387) and contrasts with the healthy situation, in which CD36 and GLUT4 have been found each to be equally distributed between endosomes and the sarcolemma (see sect. IV). These combined findings suggest that in the healthy heart and muscle CD36 and GLUT4 are stored in separate subcompartments of the recycling endosomes and that these transporters are recruited via signaling and/or trafficking proteins specific for either one of these transporters. Then, upon development of insulin resistance, alterations in the signaling and/or trafficking proteins specifically dedicated to CD36 translocation could result in a selective and permanent CD36 translocation to the sarcolemma, without a change in subcellular distribution of GLUT4. Indeed, evidence for the existence of signaling and/or trafficking events that are specifically associated with CD36 has recently been reported when the small Ras-like GTPase rab 11 (see sect. V) was observed to be attached to endosomal CD36 vesicles and not to GLUT4 vesicles (308).

Permanent CD36 relocation to the sarcolemma has also been shown to precede the loss of cardiac function, as 4 wk of high-fat feeding already resulted in increased cell surface localization of CD36 in the absence of a decrease in cardiac functional parameters, whereas a high-fat diet for 8 wk showed sustained surface presence of CD36 concomitant with decreased cardiac functioning (322). In combination with the causal relationship of increased sarcolemmal CD36 abundance and intramyocellular lipid accumulation, CD36 is beginning to be regarded as a key factor in the development of type 2 diabetes in heart and muscle.

B) **CD36 AND FATTY ACID TRANSPORT CONTRIBUTE TO INTRAMUSCULAR LIPID ACCUMULATION, NOT REDUCED FATTY ACID OXIDATION.** In view of a developing consensus that intramuscular lipids can accumulate in muscle despite concurrent increases in fatty acid oxidation, we have compared rates of CD36-mediated fatty acid transport with rates of fatty metabolism in muscles of obese Zucker rats (197). These studies have shown that plasmalemmal CD36 was again permanently relocated to the plasma membrane (197), as we had shown previously in this model (273). This plasmalemmal increase in CD36 in muscle of obese animals was highly correlated with an increased rate of fatty acid transport into muscle. Concomitantly, the rates of fatty acid esterification and oxidation were also both increased. However, in relation to the increased rate of fatty acid transport, the rate of esterification was eightfold greater than the increase in fatty acid oxidation (197). These studies strongly suggest that fatty acid transport into muscle cell is in excess of the capacity for them to be oxidized and, hence, lipids accumulate within the muscle.
Thus the CD36-mediated increase in fatty acid transport, rather than alterations in fatty acid oxidation, is the key factor contributing to the increase in intramuscular lipid accumulation in insulin-resistant muscle.

C) MECHANISMS RESPONSIBLE FOR PERMANENT CD36 RELOCATION TO THE SARCOLEMA. As detailed in sections IV A and V, in the healthy heart and skeletal muscle, fatty acid uptake is increased by insulin or by contraction due to translocation of CD36 from insulin-responsive PI3K/PKB/Akt-mediated endosomal stores or from contraction-responsive AMPK-mediated endosomal stores, respectively, to the sarcolemma. In the insulin-resistant heart, insulin was unable to further increase the already elevated basal fatty acid uptake rate, but activation of AMPK successfully further increased fatty acid uptake (91). In addition, insulin did not further increase the elevated sarcolemmal

FIG. 8. Juxtaposition of CD36 and GLUT4 in insulin-resistant muscle. Schematic presentation showing the role of the substrate transporters CD36 and GLUT4 in myocytes under healthy conditions (top) and a hypothetical model for the development of an impaired GLUT4 translocation in (pre)diabetic state (bottom). While in healthy conditions, both CD36 and GLUT4 are about equally distributed between endosomes and the sarcolemma, in the (pre)diabetic state, there is a shift in CD36 localization from the endosomes to the sarcolemma resulting in enhanced fatty acid uptake, storage of fatty acids into triacylglycerols (TAG), and subsequent inhibition of insulin signaling by fatty acid metabolites such as diacylglycerols and ceramides. Thereafter, translocation of GLUT4 from endosomes to the sarcolemma is inhibited, resulting in lowered glucose uptake and decreased incorporation into glycogen. At that stage, the muscle has become insulin resistant. FA, (long-chain) fatty acid.
CD36 pool, nor did it further deplete CD36 from the endosomal stores (91, 322). These observations suggest that insulin-responsive P3K/PKB/Akt-mediated endosomal stores are likely the source of the extra amount of CD36 present at the sarcolemma in the insulin-resistant heart. This, however, may not be the case in insulin-resistant skeletal muscle, in which plasmalemmal CD36 is also permanently upregulated (164), because in this tissue both insulin and muscle contraction failed to induce a further increase in plasmalemmal CD36 (164). The fact that skeletal muscle becomes additionally contrac- tion resistant, in contrast to heart, is a subtle difference between both tissues in the onset of insulin resistance. This is likely related to the fact that a safety system is built into the heart so that it still can increase fatty acid uptake upon increased contractile performance for the production of energy. Nonetheless, in both heart and skeletal muscle, permanent relocation of CD36 from insulin-responsive P3K/PKB/Akt-mediated endosomal stores is likely a main contributor to the development of insulin resistance.

What then are the signals that permanently deplete the insulin-responsive endosomal stores from CD36? A clue is provided by the elevated basal phosphorylation of PKB/Akt and its distal target PRAS40 in hearts from high fat fed rats, whereas AMPK activity was not affected by the diet. Moreover, increased basal PKB/Akt activity together with impaired insulin-stimulated PKB/Akt activity have been reported in skeletal muscle from ob/ob mice (301). Together these findings suggest that the elevated basal activity of PKB/Akt may contribute to the sustained presence of CD36 at the sarcolemma in insulin-resistant heart and skeletal muscle, although other diet-induced changes, for instance, in the as yet undisclosed trafficking machinery regulating CD36 endocytosis and exocytosis (see sect. Vf), might also play a role.

In prediabetic Zucker rats, plasma insulin levels are sevenfold elevated and might be responsible for CD36 relocation in heart and muscle (91, 164, 273). In contrast, systemic hyperinsulinemia was not observed in high fat diet fed rats (321). Especially this latter observation may suggest that changes in the activity of other (insulin-independent) regulators of PKB/Akt phosphorylation, such as P3Kγ- and β2-adrenergic receptor signaling pathways, CaMK, protein phosphatase 2A, and the sympathetic nervous system (126), could perhaps be responsible for elevated PKB/Akt phosphorylation and subsequent permanent CD36 relocation to the sarcolemma in the insulin-resistant heart and skeletal muscle.

D) Emerging picture of mechanisms involved. From the studies in muscles and hearts of high fat fed animals, obese Zucker rats, and ZDF rats, a picture emerges which suggests that increased rates of fatty acid transport are regulated by two mechanisms.

1) With moderate and modest insulin resistance (high fat feeding and obese Zucker rats), fatty acid trans-
port is increased by the permanent relocation of CD36 from an intracellular depot to the plasma membrane without any alteration in the protein expression of CD36 (273, 322).

2) With more severe insulin resistance (male ZDF rats, high fat fed female ZDF rats), the total cellular pool of CD36 is increased (71, 387), which likely allows for a much greater increase in CD36 at the plasma membrane.

3. Human studies

There are only a few studies that have examined fatty acid transport and transporters in human obesity and type 2 diabetes. Understandably, this work is largely descriptive and has necessarily focused on the most accessible tissues, adipose tissue (not discussed here) and skeletal muscle.

It was initially reported that skeletal muscle fatty acid uptake in human muscle is reduced in type 2 diabetes (35, 476). However, these observations are likely incorrect, because these conclusions appear to be based on problematic, indirect measurements, and the data do not concur with more recent direct determination of fatty acid transport rates across the plasma membrane in muscles of diabetic animals (71, 387) or humans with type 2 diabetes (48).

Direct determination of skeletal muscle fatty acid transport, using giant sarcolemmal vesicles, has shown that rates of fatty acid transport are markedly increased in skeletal muscle of obese individuals and those with type 2 diabetes (48). In contrast, just as in some animal models of insulin resistance (see above), skeletal muscle fatty acid transporters (FATP1 mRNA and CD36 mRNA and protein) were not altered in human obesity and type 2 diabetes (34, 48, 330), or were altered inconsistently (FABPpm protein; Refs. 48, 330, 384). Instead, the increase in rates of fatty acid transport were also positively associated with the intramuscular triacylglycerol concentration in lean, overweight, and obese individuals and type 2 diabetes patients correlated well with their increased rates of fatty acid transport (r = 0.93), an index of insulin resistance (48). Moreover, the rates of fatty acid transport were also positively associated with the intramuscular triacylglycerol concentrations (r = 0.93) (48) (Fig. 9). Notably therefore, in human obesity and type 2 diabetes, just as in animal models of insulin resistance (164, 197, 273), skeletal muscle fatty acid transport into muscle and intramuscular triacylglycerol accumulation are increased largely in association with the permanent relocation of CD36 to the plasma membrane.
membrane (48), as well as possibly a small increase in the plasmalemmal FATP4 pool (18).

4. Fiber type-specific and gender differences

A) FIBER TYPE. Skeletal muscles consist of red (oxidative) and white (glycolytic) fibers. Compared with white muscles, the red muscles have a higher capacity for fatty acid oxidation and esterification (42, 114, 164) and insulin-stimulated glucose transport (49, 165, 184, 298, 391). These differences are related, in part, to inherent differences (red > white muscle) in their expression of PGC-1α, their glucose and fatty acid transport proteins, and their enzymes for metabolizing fatty acids (23, 45, 184, 298). In view of these differences, the potential dysregulation in these processes may be greater in red muscle. Indeed, oxidative (red) muscles exhibit a 2.5-fold greater impairment in insulin-stimulated glucose transport than glycolytic (white) muscle in response to a high-fat diet (474), and ZDF rats exhibit a reduction only in red muscle GLUT4 (∼40%) but not in white muscle GLUT4 (128). In human obesity and type 2 diabetes, excess intramuscular lipid accumulation (+20 to +56%) occurs in red (I and IIA) but not in white (IIB) muscle fibers (180). There is some indication that the greater lipid accumulation in red muscles is related to muscle-specific upregulation of fatty acid transporters and transport in red muscle compared with white muscle (see below) (Fig. 10). Such fiber-specific differences could account for the accumulation of red muscle intramuscular lipids that can interfere with insulin signaling.

An increased fatty acid disposal has been observed in red but not in white muscles in the high-fat diet-induced model of insulin resistance, and this was associated with an increase in red muscle CD36 mRNA (182). Similarly, in red, but not in white muscle, fasting induced an increase in plasmalemmal FABPpm (444). In obese Zucker rats, fatty acid transport (197) and incorporation into triacylglycerol depots (197, 446) are increased more in red muscle than in white muscle. These increased rates of fatty acid transport into red muscle were twofold greater than into white obese muscle, and these differences were associated with a concomitantly greater concentration in plasmalemmal CD36 in red (increase of 100 arbitrary units) than in white muscle (increase of 25 arbitrary units) (197). Other fatty acid transporters located at the plasma membrane (FABPpm, FATP1 and -4) were not altered in either red or white muscles of obese rats (164, 197), except for one report (+61% in red muscle plasmalemmal FABPpm) (446). Along similar lines, in the transition from insulin resistance to type 2 diabetes in ZDF rats, there was an increase in red muscle, but not white muscle, fatty acid transport rates due to concomitant increases in CD36 protein expression and plasmalemmal content, while no changes occurred in either red or white muscle plasmalemmal FABPpm (71). Moreover, the increase in red muscle plasmalemmal CD36 was inversely correlated with the plasmalemmal GLUT4 (r = −0.90) (71).

Taken together, the available evidence indicates that red muscle exhibits a greater propensity for developing insulin resistance. This appears to be related, in part, to changes in intramuscular lipid accumulation in red compared with white muscle, likely as a result of changes in the expression and/or plasmalemmal content of CD36, which facilitates a greater rate of fatty acid uptake.

![Graph](https://www.prv.org/Graphs/Graph1.png)

**Fig. 9.** Triacylglycerol accumulation in human obesity and type 2 diabetes is associated with increased rates of muscle fatty acid transport and increased plasmalemmal CD36 content. Fatty acid uptake rates and CD36 were determined in giant sarcolemmal vesicles prepared from rectus abdominus muscle biopsies obtained from lean (body mass index (BMI) <25), overweight (BMI = 25–30), and obese (BMI >30) individuals and type 2 diabetics. [Redrawn from Bonen et al. (48).]

![Diagram](https://www.prv.org/Images/Diagram1.png)

**Fig. 10.** Distribution and immunolocalization of CD36 in human skeletal muscle. A cryosection of human m. vastus lateralis was stained for CD36, first by incubation with a specific anti-CD36 antibody, which was followed by incubation with a fluorescently labeled secondary antibody. Type 1 fibers were identified using antibodies specific for slow myosin heavy chain (data not shown). CD36 is more abundant in (slow oxidative) type 1 muscle fibers (indicated by 1) than in (fast glycolytic) type 2 fibers (2). At the subcellular level, CD36 immunostaining is seen both at the sarcolemma and in the cytoplasm (punctate staining pattern). [Figure courtesy of Dr. H. A. Keizer (236).]
B) GENDER DIFFERENCES. It appears that there are gender differences in insulin resistance and in the responses of fatty acid transporters to an altered fatty acid milieu and insulin. Specifically, in male rats, an acute (2 h), fourfold increase in circulating fatty acids impaired insulin signaling (IRS-1 phosphorylation, −30%; IRS-1-associated P3K activity, −48%) and induced a 40% reduction in the skeletal muscle insulin-stimulated glucose disposal rate. This was accompanied by a 50% reduction in skeletal muscle CD36 protein expression (189). Surprisingly, none of these changes was observed in female rats (189).

Considerable differences in FATP1 mRNA have also been observed among men and women. FATP1 mRNA expression in skeletal muscle is ~3.7-fold greater in lean women than in lean men (34), and insulin infusion (3 h) reduced FATP1 mRNA in lean women but not lean men, nor in obese nondiabetic and diabetic men and women (34). In addition, in women, but not in men, BMI and FATP1 mRNA were inversely related ($r = -0.74$) (34). In the absence of any measures of fatty acid transport and in the FATP proteins in these studies, it is difficult to determine the pathophysiological significance of these observations.

Clearly, the few available studies in both animals and humans do begin to suggest that there may be gender differences with respect to insulin resistance and fatty acid metabolism, including fatty acid transport and transporters. This warrants further investigation.

5. Insulin resistance in spontaneously hypertensive rats is not attributable to CD36 ablation

A series of genetic studies combining the use of cDNA microarrays, congenic mapping, and radiation hybrid mapping in spontaneously hypertensive rats (SHR), a rat model of insulin resistance and hypertension, suggested that CD36 deficiency is at the peak of linkage to the SHR alterations in fatty acid and glucose metabolism (7, 89, 337, 338). The authors concluded that CD36 deficiency provides a plausible basis for the development of insulin resistance through a primary defect in cellular fatty acid transport. Support for this notion was provided by the observation that transgenic rescue of CD36 improved insulin sensitivity (337). We fully agree with the notion that CD36 is involved in insulin resistance, but we envisage that an upregulation rather than a downregulation of CD36 is causal to insulin resistance. In fact, a possible downregulation of CD36 seems counterintuitive with regard to the accumulation of fatty acids and their metabolites in peripheral tissues. Remarkably, in contrast to the North American SHR strain used in the aforementioned studies, an SHR strain in Japan did express CD36 (146), uncoupling CD36 from the development of insulin resistance in this rodent model. The supporting evidence linking an apparent null expression of CD36 in North American SHR with insulin resistance are inconsistent. For example, transgenic expression of wild-type CD36 in the North American SHR strain increased glucose disposal (OGTT) and muscle glycogenesis and reduced circulating fatty acids (337). Yet, in subsequent work with these CD36 transgenic SHR, neither glucose disposal (OGTT) nor muscle glucose oxidation was improved (340). In stroke-prone SHR animals, lipid metabolism differed, despite similar expression of adipocyte CD36 protein (89). Moreover, other studies suggest that CD36 ablation improves insulin sensitivity (123, 147), and an increase in CD36 is linked strongly with insulin resistance (48, 91, 273), as this leads to an accumulation of intramuscular fatty acid products that can interfere with insulin signaling. From more recent work it now appears that in fact North American SHR are not null for CD36 (43). This protein is expressed in many tissues of these animals albeit at a reduced level in heart (−26%), red (−40%) and white muscles (−53%), liver (−75%), and adipose tissue (−46%) (43). Thus it is very difficult to support the proposition that the North American SHR strain fails to express CD36 protein and that a CD36 deficiency underlies insulin resistance in these animals.

C. Type 1 Diabetes

Lipid metabolism is also altered in type 1 diabetes, an effect that has been associated with altered fatty acid transport and transporters. For example, early studies indicated that heart and skeletal muscle CD36 protein expression was increased in streptozotocin (STZ)-induced diabetes, an animal model of type 1 diabetes (150, 329), suggesting an important role for this protein in taking up the increased circulating fatty acids in this model. Indeed, the intramuscular fatty acids are increased by ~25% in STZ-induced diabetic rats (312). Detailed studies of moderate and severe STZ-induced diabetes have revealed tissue-specific responses in fatty acid transport and transporters (272). The relative changes and the magnitude of changes in fatty acid transport and transporters differed among the tissues examined and/or depended on the severity of diabetes. For example, fatty acid transport increased progressively with the severity of diabetes only in the heart (moderate, +71%; severe, +143%). In skeletal muscle, fatty acid transport was upregulated to a similar extent in moderate (+37%) and severe diabetes (+28%). In contrast, in adipose tissue, fatty acid transport was not changed with moderate diabetes but upregulated (+171%) in severe diabetes (272). Concurrent with these changes in fatty acid transport, there were also concomitant changes in the protein expression and plasmalemmal content of CD36 (muscle and heart) and FABPpm (severely diabetic heart only), while in adipose tissue the CD36 plasmalemmal content, but not
its protein expression, was increased in severe diabetes. These changes in protein expression were not consistently related to changes in the mRNAs of these transporters. However, it could be shown that the changes in the rate of fatty acid transport in these different tissues was related to the presence of both CD36 and FABP<sub>pm</sub> at the plasma membrane (272). Collectively, these studies indicate that changes in CD36 and FABP<sub>pm</sub> occur in animal models of type 1 diabetes, but the extent to which these changes contribute to altered fatty acid metabolism in the STZ-induced diabetic animal model remains to be determined.

VIII. CONCLUSIONS AND PERSPECTIVES

Membrane fatty acid transporters have emerged as a group of proteins serving a pivotal role in whole body lipid metabolism. By facilitating the transmembrane transport of fatty acids, these proteins dramatically accelerate fatty acid transport into cells (and their release from adipocytes). In addition, cellular entry of fatty acids appears to be regulated acutely by changes in plasmalemmal fatty acid transporter content, which occurs in response to selected stimuli (e.g., muscle contraction, insulin) and involves the translocation of specific fatty acid transporters from an intracellular storage compartment to the plasmalemma. Fatty acid transporters thus form an integral part of a complex network of plasma and cellular proteins that enable a rapid availability and unrestricted use of fatty acids in the cell yet keep them from exerting potential harmful effects related to their amphiphilic (“soaplike”) characteristics. Finally, the occurrence of various types of fatty acid transporters with each displaying a characteristic pattern of tissue distribution further illustrates their role in cellular lipid homeostasis tuned to the metabolic requirements of a specific tissue. While the focus of this review was on heart and skeletal muscle, the concepts outlined for these tissues generally will presumably apply to all tissues with an active fatty acid metabolism.

A. Integration of Regulatory Steps

The new insights on the functioning of fatty acid transporters have further underscored the striking similarity between the regulation of the cellular utilization of fatty acids and that of glucose. A major corollary of these findings is that cellular fatty acid utilization, just like that of glucose, is regulated at three levels, i.e., 1) substrate delivery, 2) cellular uptake, and 3) intracellular metabolism (oxidation, storage, and so on, including substrate competition at the level of mitochondria).

Fatty acid transporters, just like GLUTs, function as a link among various metabolic regulatory steps aimed at adjusting cellular substrate metabolism and referred to as “metabolic coordination.” For instance, muscle contraction, through activation of AMP kinase, increases the translocation of fatty acid transporters (CD36) to the sarcolemma to increase fatty acid uptake, and concomitantly increases mitochondrial fatty acid oxidation to produce ATP needed to sustain contraction. As a result, proper functioning of fatty acid transporters is of central importance to maintain homeostasis, and derangements therein likely will result in pathology (see below).

1. Functioning of fatty acid transporters

The molecular mechanism explaining the functioning of fatty acid transporters is not yet clear. Specifically, it is not known 1) whether fatty acid transporters function alone or as a (heteromeric) complex (e.g., CD36 and FABP<sub>pm</sub>), 2) whether they act as transmembrane transporters or merely function as docking site or cell surface receptor for fatty acids, whereafter the fatty acids cross the plasma membrane by simple diffusion, 4) whether the functioning of fatty acid transporters is dependent on or influenced by accessory proteins or by the lipid microenvironment, and finally 5) whether posttranslational modifications (palmitylation, phosphorylation) would further influence their functioning. Importantly, the mode of action of fatty acid transporters may also differ among the key tissues involved in fatty acid handling. In this respect, it has been shown that the protein expression of each of the fatty acid transporters (FABP<sub>pm</sub>, CD36, FATP4, but not FATP1) is graded among muscle tissues in relation to their well-known differences in fatty acid utilization, i.e., heart >> red muscle > white muscle (45, 197, 286, 314, 329, 459). However, absolute quantities have been assessed only for CD36 (329) so that a quantitative comparison among fatty acid transporters is not yet possible.

Further insight into the molecular functioning of fatty acid transporters could also be obtained from their three-dimensional protein structures. However, unfortunately, a detailed structure is not yet known for any of the fatty acid transporters (cf. Fig. 1, B and C). Although computer predictions of the protein structure based on the primary amino acid sequence have been presented for CD36 (156) and FATP (107), and some protein characteristics are known for FABP<sub>pm</sub> (419), these models must be interpreted with great caution as they may not represent the real structure.
It has been argued that each of the fatty acid transporters also is known to support other metabolic functions, e.g., mitochondrial AspAT (FABPpm), multifunctional ligand receptor (CD36), and (very-long-chain) acyl-CoA synthetase (FATPs) (see sect. II). These findings have been interpreted to suggest that their functioning in cellular fatty acid uptake is artifactual. However, it should be noted that assigning dual functions to specific proteins is not uncommon. For instance, β-catenin functions in both cellular adhesion and transcriptional regulation (53), and integrins function both in cell adhesion and in cellular signaling (303).

2. Is protein-mediated fatty acid transport rate-limiting in fatty acid utilization?

In heart and muscle, glucose uptake mediated by the glucose transporter GLUT4, except during exercise (130), is considered the rate-limiting step in cellular glucose utilization (for review, see Refs. 207, 365, 428). Similarly, but perhaps not during exercise (242), it is also possible that protein-mediated fatty acid transport across the sarcolemma is rate-limiting in cardiac and muscular fatty acid utilization. Several lines of evidence do support this view.

First, the intracellular fatty acid concentration remains low at saturating fatty acid concentrations (see sect. II). This observation does not only indicate that the saturation kinetics of cellular fatty acid uptake reflects saturation of sarcolemmal transport rather than saturation of metabolism (287), but also supports the notion that fatty acid uptake may be a rate-limiting step in cardiac and muscular fatty acid utilization (285). Second, the fatty acid uptake kinetics in the presence (cardiac myocytes) and absence of metabolism (giant sarcolemmal vesicles) display a similar apparent $K_m$ for fatty acid uptake (285, 286). Third, a recent study (283) showed that CPT-I, which converts fatty acyl-CoA into fatty acyl-β-carnitine and is generally thought to be the rate-limiting step in cardiac fatty acid utilization (for review, see Ref. 296), cannot be the only parameter governing the rate of fatty acid utilization. Specifically, a chronic partial (~50%) inhibition of CPT-I by administration of etomoxir to rats did not affect fatty acid uptake and metabolism by cardiac myocytes (283), strongly arguing against CPT-I as the primary site determining cardiac fatty acid fluxes. As a result, other sites in cardiac fatty acid utilization, most notably sarcolemmal protein-mediated fatty acid transport, may also function in regulating cardiac fatty acid flux. The mechanism of such regulation may differ among the various fatty acid transporters but will include intracellular translocation of fatty acid transporters to the plasma membrane (see sect. IVA) and to mitochondria (see sect. IVC), and may also comprise modulation of their involvement by, for instance, changes in the interaction with accessory proteins.

B. Fatty Acid Transporters as Potential Therapeutic Targets

The role of fatty acid transporters in the control of cellular fatty acid uptake under normal conditions and their implication in metabolic alterations occurring in certain disease conditions suggest that fatty acid transporters are an attractive therapeutic target to manipulate cellular fatty acid utilization. This would apply especially to obesity and insulin resistance whereby increased rates of fatty acid transport are a key factor contributing to the intracellular lipid accumulation in heart and muscle tissue, which in turn interferes with the insulin signal transduction cascade required to induce GLUT4 translocation (see sect. VII). Indeed, in studies in which CD36 has been ablated (147) or in which the increase in plasmalemmal CD36 content has been prevented (387), there is clear evidence of an improved insulin sensitivity (i.e., blunting the progression of high-fat diet-induced insulin resistance). In addition, CD36 ablation was found to rescue myocardial lipotoxicity and myocardial dysfunction induced by PPARα overexpression (480). To date, there are as yet no effective pharmacological agents that specifically inhibit fatty acid transport. Unfortunately, the CD36 inhibitor SSO is unsuitable for use in vivo due to its limited stability in solution. Nevertheless, development of inhibitors that limit fatty acid uptake would represent a novel therapeutic strategy against insulin resistance.

In a broader perspective, manipulation of cellular substrate uptake by modulating the presence or functioning of specific substrate transporters in the plasma membrane has been suggested as a means to alter cellular substrate preference (140). Such an approach is expected to be of interest not only for heart (140) but also for skeletal muscle, as intermediary metabolism is regulated similarly in these organs while both are sensitive to a chronic change in the balance of glucose and fatty acid utilization. Theoretically, modulating the cellular distribution of, in particular, the substrate transporters GLUT4 and CD36 in the diseased heart or muscle may normalize substrate metabolism and allow them to function normally. In practice this would require the selective recruitment of either GLUT4 or CD36 to the membrane, or their selective internalization, while so far it was found that these transporters respond to physiological stimuli (contraction, insulin) by their simultaneous recruitment (see sect. IVB). However, proof of concept for such selectivity comes from studies in rat cardiomyocytes indicating that arsenite (282) and dipiridamole (274) specifically recruit GLUT4 and CD36, respectively, leading to selectively increased glucose and fatty acid utilization, respectively.
Although the intracellular targets of these pharmacological compounds are not known, most likely they activate or inhibit trafficking proteins specifically involved in either GLUT4 or CD36 translocation (376). As a result, these recent findings illustrate the feasibility of the general concept that selective transporter translocation can be applied to alter substrate preference and thus holds promise as a target for so-called metabolic modulation therapy (422).

ACKNOWLEDGMENTS

We thank Dr. Robert W. Schwenk for assistance with the illustrations.

Addresses for reprint requests and other correspondence: J. F. C. Glatz and J. J. F. P. Luiken, Dept. of Molecular Genetics, McMaster University, PO Box 616, NL-6200 MD Maastricht, The Netherlands (e-mail: glatz@gen.unimaas.nl; jluiken@gen.unimaas.nl); A. Bonen, Dept. of Human Health and Nutritional Sciences, University of Guelph, Guelph, Ontario Canada, N1G 2W1 (e-mail: abonen@uguelph.ca).

GRANTS

Studies in the authors’ laboratories were supported by the Netherlands Organization for Health Research and Development (NWO-ZonMw Grant 912-04-075), the European Commission (Integrated Project LSHM-CT-2004-005272, Exgenesis), the Natural Sciences and Engineering Research Council of Canada, the Canadian Foundation for Innovation, the Heart and Stroke Foundation of Ontario, the Canadian Institutes of Health Research, and the Canada Research Chair program.

J. F. C. Glatz is Netherlands Heart Foundation Professor of Cardiac Metabolism.

J. J. F. P. Luiken was the recipient of a VIDI-Innovational Research Award from the Netherlands Organization for Scientific Research.

A. Bonen is the Canada Research Chair in Metabolism and Health.

REFERENCES

Fatty Acid Transporters and Lipid Metabolism


Downloaded from http://physrev.physiology.org/ by 10.220.33.1 on April 6, 2017.
Curtis BR, Aster RH. Incidence of the Nak(a)-negative platelet phenotype in African Americans is similar to that of Asians. Transfusion 36: 331–334, 1996.


De Feyter HM, van den Broek NM, Praet SF, Nicolay K, van der Sluijs P. Incidence of the Nak(a)-negative platelet phenotype in African Americans is similar to that of Asians. BMC Cell Biol 9: 45, 2008.


Physiol Rev • VOL 90 • JANUARY 2010 • www.pvr.org
FATTY ACID TRANSPORTERS AND LIPID METABOLISM


169. Hawley SA, Boudou J, Reid JL, Mustard KJ, Udd L, Makela TP, Alessi DR, Hardie DG. Complexes between the LKB1 tumor


FATTY ACID TRANSPORTERS AND LIPID METABOLISM